Search Result
Results for "
oral glucose
" in MedChemExpress (MCE) Product Catalog:
6
Biochemical Assay Reagents
15
Isotope-Labeled Compounds
Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-12611
-
GW-869682X
|
SGLT
|
Metabolic Disease
|
Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes .
|
-
-
- HY-14771A
-
-
-
- HY-153865
-
PF-07081532
|
GLP Receptor
|
Metabolic Disease
|
Lotiglipron (PF-07081532) is an orally active GLP-1R agonist. Lotiglipron reduces glucose and body weight, and can be used for research of Type 2 diabetes mellitus (T2DM) .
|
-
-
- HY-A0231
-
Gondafon; Glycodiazine
|
Insulin Receptor
|
Metabolic Disease
|
Glymidine sodium is an oral active antidiabetic. Glymidine sodium is the inhibitor of hepatic lipolysis. Glymidine sodium inhibits the glucose formation and supresses the elevated pyruvate oxidation which results from the inhibition of endogenous lipid mobilization .
|
-
-
- HY-N12353
-
|
Phosphatase
|
Metabolic Disease
|
Stevisalioside A (Compound 2) can be isolated from Stevia serrata roots. Stevisalioside A is an orally active antidiabetic agent. Stevisaliosides A inhibits PTP1B (IC50: 526.8 μM). Stevisalioside A reduces blood glucose levels and the postprandial peak in oral glucose and insulin tolerance tests in Streptozotocin (HY-13753) induced hyperglycemic mice .
|
-
-
- HY-148684
-
|
AMPK
|
Metabolic Disease
|
AMPK activator 10 is an orally active, potent AMPK activator with EC150 of 44.3 nM by cell-ELISA. AMPK activator 10 increases the phosphorylation levels of ACC. AMPK activator 10 exhibits a glucose lowering effect .
|
-
-
- HY-149409
-
|
Glycosidase
|
Metabolic Disease
|
α-Glucosidase-IN-31 (compound R1) is an orally active, potent α-Glucosidase inhibitor with an IC50 value of 10.1 μM. α-Glucosidase-IN-31 significantly reduces the blood glucose level and has antidiabetic activity .
|
-
-
- HY-121565
-
|
Insulin Receptor
|
Metabolic Disease
Endocrinology
|
SaRI 59-801 is an orally effective hypoglycemic compound with stimulation activity of insulin secretion. SaRI 59-801 decreases blood glucose in several species and to elevate plasma insulin in rats and mice .
|
-
-
- HY-14771
-
-
-
- HY-122083
-
|
PPAR
|
Metabolic Disease
|
T2384 is a peroxisome proliferator-activated receptor γ (PPARγ) ligand. T2384 also is an orally active antidiabetic agent. T2384 reduces the fasting plasma glucose levels and plasma insulin levels .
|
-
-
- HY-103433
-
|
Dipeptidyl Peptidase
|
Metabolic Disease
|
K579 is a potent and orally active dipeptidyl peptidase IV inhibitor. K579 inhibits the blood glucose elevation. K579 increases the plasma insulin and active forms of glucagon-like peptide-1 (GLP-1). K579 has the potential for the research of diabetic .
|
-
-
- HY-151138
-
|
Glycosidase
|
Metabolic Disease
|
α-Glucosidase-IN-16 is a potent and orally active α-glucosidase inhibitor with an IC50 value of 3.28 μM. α-Glucosidase-IN-16 can reduce the level of blood glucose in Streptozotocin-induced diabetic rats. Antidiabetic activity .
|
-
-
- HY-109500
-
meso-Nordihydroguaiaretic acid; meso-NDGA
|
Lipoxygenase
|
Metabolic Disease
Cancer
|
Masoprocol (meso-Nordihydroguaiaretic acid) is a potent and orally active lipoxygenase inhibitor. Masoprocol shows antihyperglycemic activity. Masoprocol decreases the glucose concentration and hepatic triglyceride in vivo. Masoprocol has the potential for the research of type II diabetes .
|
-
-
- HY-148189
-
LXY-05-029
|
AMPK
|
Metabolic Disease
|
Aldometanib (LXY-05-029) is an orally active aldolase inhibitor. Aldometanib can activate lysosomal adenosine monophosphate-activated protein kinase (AMPK) and decreases blood glucose. Aldometanib can be used for the research of metabolic homeostasis .
|
-
-
- HY-130120
-
|
Free Fatty Acid Receptor
PPAR
|
Metabolic Disease
|
HWL-088 is a highly potent and orally active free fatty acid receptor 1 (FFA1/GPR40) agonist (EC50 of 18.9 nM) with moderate PPARδ activity (EC50 of 570.9 nM) . HWL-088 improves glucose and lipid metabolism, and has anti-diabetic effects .
|
-
-
- HY-121798
-
|
PPAR
|
Metabolic Disease
|
TZD18 is a potent and orally active PPARα and PPARγ dual agonist with IC50 values of 0.028, 0.057, >10 µM for PPARα, PPARγ, PPARδ, respectively. TZD18 reduces plasma levels of both glucose and triglycerides in diabetic mice. TZD18 has the potential for the research of type 2 diabetes .
|
-
-
- HY-139605
-
|
GLUT
|
Inflammation/Immunology
Cancer
|
GLUT inhibitor-1 is a potent and orally active inhibitor of glucose transporters, targeting both GLUT1 and GLUT3, with IC50s of 242 nM and 179 nM, respectively. GLUT inhibitor-1 has the potential for the reaesrch of cancers and autoimmune diseases .
|
-
-
- HY-106697
-
ICI 128436
|
Aldose Reductase
|
Metabolic Disease
|
Ponalrestat (ICI 128436) is an orally active, selective and noncompetitive aldose reductase (AKR1B1; ALR) inhibitor. Ponalrestat selectively inhibits ALR2 (Ki=7.7 nM) over ALR1 (Ki=60 μM). Ponalrestat inhibits the conversion of glucose to sorbitol .
|
-
-
- HY-100017
-
|
GLUT
Disulfidptosis
|
Cancer
|
BAY-876 is an orally active and selective glucose transporter 1 (GLUT1) inhibitor with an IC50 of 2 nM. BAY-876 is >130-fold more selective for GLUT1 than GLUT2, GLUT3, and GLUT4. BAY-876 is also a potent blocker of glycolytic metabolism and ovarian cancer growth. In addition, BAY-876 can induce the formation of disulfide bonds in actin cytoskeletal proteins, leading to the occurrence of cellular disulfidptosis .
|
-
-
- HY-14945
-
GSK189075
|
SGLT
|
Metabolic Disease
|
Remogliflozin etabonate (GSK189075) is an orally active, selective and low-affinity sodium glucose cotransporter (SGLT2) inhibitor with Ki values of 1.95 μM, 2.14 μM, 43.1 μM, 8.57 μM for hSGLT2, rSGLT2, hSGLT1, rSGLT1, respectively. Remogliflozin etabonate is a proagent based on benzylpyrazole glucoside and is metabolized to its active form, Remogliflozin, in the body. Remogliflozin etabonate exhibits antidiabetic efficacy in rodent models .
|
-
-
- HY-10289
-
RO-4876904
|
Dipeptidyl Peptidase
P-glycoprotein
|
Cardiovascular Disease
Metabolic Disease
|
Carmegliptin (RO-4876904) is an orally active, potent and long-acting dipeptidyl peptidase IV inhibitor. Carmegliptin is also a substrate of P-glycoprotein that synergizes with Verapamil (HY-14275). Carmegliptin improves insulin sensitivity and reduces hepatic glucose production in hyperglycemic mice. Carmegliptin is promising for research of type 2 diabetes, hypertension and cardiovascular disease .
|
-
-
- HY-W005629
-
|
Cannabinoid Receptor
PDK-1
|
Metabolic Disease
Cancer
|
Leelamine is an orally active pyruvate dehydrogenase kinase (PDK) inhibitor with an IC50 value of 9.5 μM, showing a blood glucose lowering effect in the diabetic mouse. Leelamine is also a weak agonist of cannabinoid receptors CB1 and CB2. Leelamine decreases mitotic activity, prostate-specific antigen expression and induces Apoptosis to cell death in cancer cells .
|
-
-
- HY-142295
-
|
DYRK
|
Metabolic Disease
|
GNF2133 is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 has the potential for the research of type 1 diabetes .
|
-
-
- HY-142295A
-
|
DYRK
|
Metabolic Disease
|
GNF2133 hydrochloride is a potent, selective and orally active DYRK1A inhibitor with IC50s of 0.0062, >50 µM for DYRK1A and GSK3β, respectively. GNF2133 hydrochloride shows good proliferation potency and efficacy on rat and human primary β-cell. GNF2133 hydrochloride significantly improves glucose disposal capacity and increases insulin secretion. GNF2133 hydrochloride has the potential for the research of type 1 diabetes .
|
-
-
- HY-N2486
-
|
Fatty Acid Synthase (FASN)
Apoptosis
|
Cancer
|
Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects.
|
-
-
- HY-162893
-
|
Glycosidase
|
Metabolic Disease
|
SX29 is an orally active non-competitive α-glucosidase inhibitor with an IC50 value of 2.12 μM. SX29 exhibits hypoglycemic activity, and oral administration of SX29 can reduce blood glucose levels and improve glucose tolerance in diabetic mice .
|
-
-
- HY-N7912
-
(2S)-Pterosin A
|
Others
|
Metabolic Disease
|
Pterosin A is an orally active anti-diabetic agent. Pterosin A promotes glucose uptake, increases serum insulin, and improves hyperglycemia and glucose intolerance in diabetic mice. Pterosin A can be isolated from Pteridium aquilinum .
|
-
-
- HY-109018A
-
|
SGLT
|
Metabolic Disease
|
Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .
|
-
-
- HY-109018
-
|
SGLT
|
Metabolic Disease
|
Velagliflozin is an orally available sodium-glucose cotransporter 2 (SGLT2) inhibitor, with anti-diabetic activity.
|
-
-
- HY-N2486R
-
|
Fatty Acid Synthase (FASN)
Apoptosis
|
Cancer
|
Desoxyrhaponticin (Standard) is the analytical standard of Desoxyrhaponticin. This product is intended for research and analytical applications. Desoxyrhaponticin is a kind of oral drug that inhibits effective fatty acid synthesis (FASN), and has a fatal effect on cancer cells. Desoxyrhaponticin has the ability to inhibit glucose uptake, improve oral glucose tolerance as a diabetic agent, and possess anti-diabetic effects .
|
-
-
- HY-122613
-
|
SGLT
|
Metabolic Disease
|
YM543 free base is a potent and orally active sodium-glucose cotransporter (SGLT) 2 inhibitor. YM543 free base reduces blood glucose levels. YM543 free base can be used in research of diabetes .
|
-
-
- HY-14810
-
AVE-2268
|
SGLT
|
Metabolic Disease
|
Atigliflozin (AVE-2268) is an orally active and selective SGLT-2 inhibitor, with IC50s of 10 nM and 8.2 μM for hSGLT-2 and hSGLT-1) respectively. Atigliflozin can lower the blood glucose and improve the impaired oral glucose tolerance. Atigliflozin can be used for research of type II diabetes mellitus .
|
-
-
- HY-109018B
-
|
SGLT
|
Metabolic Disease
|
Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .
|
-
-
- HY-161281
-
|
Glycosidase
|
Metabolic Disease
|
α-Glucosidase-IN-49 (compound C23) is a potent inhibitor of α-Glucosidase, with IC50 of 0.52 μM. α-Glucosidase-IN-49 has oral bioactivity that can reduce blood glucose and improve glucose tolerance in mice .
|
-
-
- HY-138842
-
|
Insulin Receptor
Akt
ERK
|
Metabolic Disease
|
DDN is a selective insulin receptor (Insulin Receptor) activator, an insulin sensitizer, and a glucose-lowering insulin mimetic with oral bioavailability. DDN can directly bind to the receptor kinase domain and induce Akt and ERK phosphorylation, and it can also enhance insulin's effect on glucose uptake. DDN significantly reduces blood glucose levels in wild-type and diabetic ob/ob and db/db mice .
|
-
-
- HY-119322
-
NN414
|
Potassium Channel
|
Metabolic Disease
|
Tifenazoxide (NN414) is a potent, orally active and SUR1/Kir6.2 selective K ATP channels opener. Tifenazoxide has antidiabetic effect, can inhibit glucose stimulated insulin release in vitro and in vivo, and has a beneficial effect on glucose homeostasis .
|
-
-
- HY-113878
-
-
-
- HY-107129
-
|
GCGR
|
Metabolic Disease
|
MK-3577 is an orally effective glucagon receptor (GCGR) antagonist that reduces hepatic glucose production and lowers blood glucose levels by blocking glucagon receptors on target organs, primarily the liver. Pharmacokinetic analysis in domestic cats indicates that MK-3577 reaches peak levels 3 to 4 hours after oral administration, with a half-life of approximately 15 hours. MK-3577 can be used in diabetes research .
|
-
-
- HY-153617
-
|
FOXO
|
Metabolic Disease
|
FOXO1-IN-3 is a highly-selective and orally active FOXO1 inhibitor. FOXO1-IN-3 reduces hepatic glucose production in mice. FOXO1-IN-3 improves insulin sensitivity and glucose control in db/db mice without causing weight gain .
|
-
-
- HY-110197
-
6bK TFA
1 Publications Verification
|
Insulin Receptor
|
Metabolic Disease
|
6bK TFA is a potent and selective insulin degrading enzyme (IDE) inhibitor with an IC50 value of 50 nM. 6bK TFA increases circulating insulin in high-fat-fed mice. Acute administration of 6bK TFA enhances glucose tolerance to oral glucose, notably to a greater extent in high-fat-fed mice .
|
-
-
- HY-N0936
-
Coixol
1 Publications Verification
6-Methoxy-2-benzoxazolinone; 6-MBOA
|
Others
|
Inflammation/Immunology
|
Coixol (6-Methoxy-2-benzoxazolinone;6-MBOA) is a polyphenol extracted from coix (Coix lachryma-jobi L.var.ma-yuen Stapf) with antimicrobial and antitumor activities .
|
-
-
- HY-120872
-
|
Glycosyltransferase
|
Metabolic Disease
|
AJS1669 free acid is a potent and orally available glycogen synthase (GS) activator. AJS1669 improves glucose metabolism and reduces body fat mass in mice[1].
|
-
-
- HY-19843A
-
|
Glucokinase
|
Metabolic Disease
|
MK-0941 free base is an orally active glucokinase activator, with EC50s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 free base exhibits strong glucose-lowering activity and is a potential therapeutic agent for treatment of type 2 diabetes .
|
-
-
- HY-144289
-
|
Glucokinase
|
Metabolic Disease
|
BMS-820132 is an orally active and partial glucokinase (GK) activator with a AC50 of 29 nM. BMS-820132 decreases the glucose levels in glucose tolerance test (OGTT) model in normal rats, but not Zucker diabetic fatty (ZDF) rats. BMS-820132 exhibits pharmacological toxicity secondary to strong GK activation .
|
-
-
- HY-109144
-
DWP-16001
|
SGLT
|
Metabolic Disease
|
Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor .
|
-
-
- HY-164781
-
-
-
- HY-117880
-
CORT 125281
|
Glucocorticoid Receptor
|
Metabolic Disease
Endocrinology
|
Exicorilant (CORT 125281) is a selective and oral active glucocorticoid receptor (GR) antagonist, with a Ki value of 7 nM . Exicorilant (CORT 125281) has potential to overcome adiposity, glucose intolerance and dyslipidaemia .
|
-
-
- HY-161892
-
|
FABP
|
Metabolic Disease
Inflammation/Immunology
|
FABP4-IN-4 (Compound 30) is an orally active inhibitor for FABP, with IC50 of 1.18 μM for FABP 1. FABP4-IN-4 improves the glucose tolerance, reduces the level of blood glucose, plasma lipids and hepatic inflammatory factors, attenuates hepatic steatosis, and exhibits anti-inflammatory effects in mouse diet-induced obesity models .
|
-
-
- HY-145597
-
|
GLUT
Disulfidptosis
|
Metabolic Disease
Cancer
|
KL-11743 is a potent, orally active, and glucose-competitive inhibitor of the class I glucose transporters, with IC50s of 115, 137, 90, and 68 nM for GLUT1, GLUT2, GLUT3, and GLUT4, respectively. KL-11743 specifically blocks glucose metabolism. KL-11743 can synergize with electron transport inhibitors to induce cell death. In addition, KL-11743 can induce the formation of disulfide bonds in actin cytoskeletal proteins, leading to the occurrence of cellular disulfidptosis .
|
-
-
- HY-117755
-
|
AMPK
|
Metabolic Disease
|
PF-739 is an orally active and non-selective activator of AMPK. PF-739 activates 12 heterotrimeric AMPK complexes and significantly reduces the level of glucose in plasma complexes .
|
-
- HY-162042
-
|
AMPK
|
Metabolic Disease
|
AMPK activator 14 (compound 32) is an orally active AMPK activator. AMPK activator 14 decreases fasted glucose and insulin levels in a db/db mouse model of Type II diabetes .
|
-
- HY-120160
-
CP-86325
|
PPAR
|
Neurological Disease
Metabolic Disease
|
Darglitazone (CP-86325), a thiazolidinedione, is a potent, selective, and orally active PPAR-γ agonist. Darglitazone is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research .
|
-
- HY-19843
-
|
Glucokinase
|
Metabolic Disease
|
MK-0941 is a selective, orally active, and allosteric glucokinase activator with EC50s of 240 and 65 nM for recombinant human glucokinase in the presence of 2.5 and 10 mM glucose, respectively. MK-0941 activates hexokinase subtype IV. MK-0941 can increase insulin secretion and glucose uptake. MK-0941 can be studied in research for type 2 diabetes .
|
-
- HY-160602
-
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
CPL207280 is an orally active GPR40/FFA1 agonist with an antidiabetic effect. CPL207280 can effectively enhance glucose-stimulated insulin secretion and improve glucose tolerance in MIN6 pancreatic β-cells as well as in healthy Wistar Han rats and diabetic rat models. CPL207280 can be used for the research of type 2 diabetes .
|
-
- HY-120160A
-
CP 86325 Sodium
|
PPAR
|
Neurological Disease
Metabolic Disease
|
Darglitazone Sodium, a thiazolidinedione, is an orally active, potent, and selective PPAR-γ (peroxisome proliferator-activated receptor) agonist. Darglitazone Sodium is effective in controlling blood glucose and lipid metabolism, and can be used for type II diabetes research .
|
-
- HY-P1124
-
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
AS2034178 free base, a specific and orally active GPR40 agonist, exhibits glucose-dependent insulin secretion enhancement. AS2034178 free base has potential for type 2 diabetes mellitus research .
|
-
- HY-N11551
-
|
Others
|
Others
Metabolic Disease
|
Salvifaricin is an orally active diterpenoid compound that can be isolated from Salvia leucantha Cav. and Salvia hispanica L.. Salvifaricin significantly reduces fasting blood glucose and serum triglyceride (TG) levels, and has anti-diabetic effect .
|
-
- HY-153113
-
DJT1116PG
|
SGLT
|
Endocrinology
|
Rongliflozin (DJT1116PG) is a selective and orally active inhibitor of sodium-glucose co-transporter-2 (SGLT-2). Rongliflozin can be used for the research of type 2 diabetes mellitus (T2DM) .
|
-
- HY-12976
-
|
G Protein-coupled Receptor Kinase (GRK)
|
Metabolic Disease
|
DS-1558 is an orally active small molecule G protein-coupled receptor 40 agonist. DS-1558 not only increases the glucose-stimulated insulin secretion by glucagon like peptide-1 (GLP-1) but also potentiated the maximum insulinogenic effects of GLP-1 after an intravenous glucose injection in normal Sprague Dawley rats. DS-1558 is promising for research of type 2 diabetes .
|
-
- HY-173130
-
|
Glycosidase
|
Metabolic Disease
Inflammation/Immunology
|
α-Glucosidase-IN-86 (Compound A4) is an orally active α-glucosidase inhibitor with an IC50 of 2.72 μM. α-Glucosidase-IN-86 has high safety in mice. α-Glucosidase-IN-86 can reduce fasting blood glucose levels, improve glucose tolerance, regulate blood lipids, and has antioxidant effects in diabetic mice. α-Glucosidase-IN-86 can be used for the research of diabetes .
|
-
- HY-N9386
-
Eugeniin
|
Bacterial
Antibiotic
|
Infection
Neurological Disease
Inflammation/Immunology
|
Tellimagrandin II (Eugeniin), with oral activity, is the first intermediate of the ellagitannin series derived from 4C1-glucose. It inhibits the resistance of Staphylococcus aureus by disrupting the integrity of the cell wall, leading to the loss of cytoplasmic contents. Additionally, Tellimagrandin II exhibits anti-inflammatory effects and inhibits acetylcholinesterase (AChE) activity, improving memory impairment. Tellimagrandin II holds potential for research in the fields of antibacterial, anti-inflammatory, and neurodegenerative diseases .
|
-
- HY-108328
-
PF-04937319
|
Glucokinase
|
Neurological Disease
Metabolic Disease
|
Nerigliatin (PF-04937319) is a orally active glucokinase activator (GKA) with EC50 value of 154.4 μM. Nerigliatin maintains glucose-lowering efficacy. Nerigliatin causes peripheral nerve degeneration. Nerigliatin can be used in type 2 diabetes research.
|
-
- HY-101903AR
-
|
Reference Standards
FABP
|
Cardiovascular Disease
Metabolic Disease
|
BMS-309403 (sodium) (Standard) is the analytical standard of BMS-309403 (sodium). This product is intended for research and analytical applications. BMS-309403 sodium is a potent, orally active, and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor, with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 sodium interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 sodium improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .
|
-
- HY-101903R
-
|
Reference Standards
FABP
|
Cardiovascular Disease
Metabolic Disease
|
BMS-309403 (Standard) is the analytical standard of BMS-309403. This product is intended for research and analytical applications. BMS-309403 is a potent, orally active and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .
|
-
- HY-101903A
-
|
FABP
|
Cardiovascular Disease
Metabolic Disease
|
BMS-309403 sodium is a potent, orally active, and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor, with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 sodium interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 sodium improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .
|
-
- HY-101903
-
|
FABP
|
Cardiovascular Disease
Metabolic Disease
|
BMS-309403 is a potent, orally active and selective adipocyte fatty acid binding protein (also known as FABP4, aP2) inhibitor with Kis of <2, 250, and 350 nM for FABP4, FABP3, and FABP5, respectively. BMS-309403 interacts with the fatty-acid-binding pocket within the interior of the protein and competitively inhibits the binding of endogenous fatty acids. BMS-309403 improves endothelial function in apolipoprotein E-deficient mice and in cultured human endothelial cells .
|
-
- HY-15461
-
PF-04971729
|
SGLT
|
Metabolic Disease
|
Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .
|
-
- HY-19176
-
|
Insulin Receptor
|
Metabolic Disease
|
S-15261 is an orally active and potent anti-hyperglycemic agent. S-15261 reduces hepatic glucose production through direct and insulin-sensitizing effects. S-15261 can be used for the research of insulin resistance syndrome .
|
-
- HY-125327
-
|
SGLT
|
Metabolic Disease
|
YM-543 is a selective SGLT2 inhibitor that effectively reduces hyperglycemia in type 2 diabetic mice through increased urinary glucose excretion. YM-543 demonstrates potent inhibition of both mouse and human SGLT2 activities at nanomolar concentrations. YM-543, when administered orally, significantly improves glucose tolerance in diabetic models and sustains its effects for over 12 hours. YM-543, in combination with other antidiabetic agents like rosiglitazone or metformin, enhances the therapeutic effects on diabetic symptoms. YM-543 does not affect blood glucose levels in normal mice, indicating its specificity for diabetic conditions.
|
-
- HY-168706
-
|
Phosphatase
|
Metabolic Disease
|
LXQ-87 is an oral noncompetitive inhibitor of PTP1B with an IC50 of 1.061 μM, showing hypoglycemic activity. LXQ-87 alleviates insulin resistance and promotes cellular glucose uptake, making it useful for research on type 2 diabetes .
|
-
- HY-14860A
-
Duvoglustat hydrochloride
|
Glycosidase
PI3K
Bacterial
Antibiotic
|
Infection
Metabolic Disease
|
1-Deoxynojirimycin hydrochloride (Duvoglustat hydrochloride) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin hydrochloride suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin hydrochloride possesses antihyperglycemic, anti-obesity, and antiviral features .
|
-
- HY-14860
-
Duvoglustat
|
Glycosidase
PI3K
|
Metabolic Disease
|
1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features .
|
-
- HY-10449A
-
TS 071 hydrate
|
SGLT
|
Metabolic Disease
|
Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC50 of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM) .
|
-
- HY-18686
-
|
Phosphatase
Akt
|
Metabolic Disease
|
AS1949490 is a potent, orally active, selective SHIP2 phosphatase inhibitor with IC50 values of 0.34, 0.62, 13, >50, >50, and >50 µM for Mouse SHIP2, Human SHIP2, Human SHIP1, Human PTEN, Human synaptojanin, and Human myotubularin, respectively. AS1949490 increases the phosphorylation of Akt, glucose consumption and glucose uptake. AS1949490 activates intracellular insulin signalling pathways. AS1949490 can be used for research of diabetes .
|
-
- HY-176040
-
-
- HY-142114
-
|
Arrestin
|
Metabolic Disease
|
SRI-37330 is an orally bioavailable thioredoxin-interacting protein (TXNIP) inhibitor. SRI-37330 inhibits glucagon secretion and function, reduces hepatic glucose production and reverses hepatic steatosis. SRI-37330 can be used for type 2 diabetes research .
|
-
- HY-W010655
-
TAK-875 hemihydrate
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
Fasiglifam (TAK-875) hemihydrate is a potent, selective and orally active GPR40 agonist with EC50 of 72 nM. Fasiglifam enhances glucose-dependent insulin secretion and improves hyperglycemia in type 2 diabetic rats. Fasiglifam can induce liver injury .
|
-
- HY-106158
-
|
SGLT
|
Metabolic Disease
|
T-1095 is a selective and orally active Na +-glucose cotransporter (SGLT) inhibitor with IC50s of 22.8 µM and 2.3 µM for human SGLT1 and SGLT2, respectively. T-1095 can be used for diabetes research .
|
-
- HY-141623
-
|
Arrestin
|
Metabolic Disease
|
SRI-37330 hydrochloride is an orally bioavailable thioredoxin-interacting protein (TXNIP) inhibitor. SRI-37330 hydrochloride inhibits glucagon secretion and function, reduces hepatic glucose production and reverses hepatic steatosis. SRI-37330 hydrochloride can be used for type 2 diabetes research .
|
-
- HY-114308
-
|
SGLT
|
Metabolic Disease
|
SGL5213 is a potent, oral active and low-absorbable sodium-dependent glucose cotransporter 1 (SGLT1) inhibitor, with IC50 values of 29 nM and 20 nM for hSGLT1 and hSGLT2, respectively. SGL5213 has potential to treat type 2 diabetes treatment .
|
-
- HY-12413A
-
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
BMS-986118 is a potent, orally active, and selective GPR40 agonist with an EC50 of 0.07 µM. BMS-986118 has dual insulinotropic and GLP-1 secretory effects, resulting in robust plasma glucose lowering effects in acute animal models .
|
-
- HY-A0132S14
-
N-Acetyl-2-amino-2-deoxy-D-glucose-d3
|
Isotope-Labeled Compounds
Endogenous Metabolite
Drug Derivative
Interleukin Related
Drug Isomer
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
N-Acetyl-D-glucosamine-d3 (N-Acetyl-2-amino-2-deoxy-D-glucose-d3) is deuterium labeled N-Acetyl-D-glucosamine. N-Acetyl-D-Glucosamine (N-Acetyl-2-amino-2-deoxy-D-glucose), the D isomer of N-acetylglucosamine, is an orally active monosaccharide derivative of glucose with anti-tumor and anti-inflammation properties. N-Acetyl-D-Glucosamine is also a bacterial metabolite, which is found in Escherichia coli. N-Acetyl-D-Glucosamine can induce yeast-mycelial conversion in Candida albicans. N-Acetyl-D-Glucosamine also enhances healing of cartilaginous injuries in rabbits .
|
-
- HY-A0132
-
N-Acetyl-2-amino-2-deoxy-D-glucose
|
Endogenous Metabolite
Drug Derivative
Drug Isomer
Interleukin Related
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
N-Acetyl-D-Glucosamine (N-Acetyl-2-amino-2-deoxy-D-glucose), the D isomer of N-acetylglucosamine, is an orally active monosaccharide derivative of glucose with anti-tumor and anti-inflammation properties. N-Acetyl-D-Glucosamine is also a bacterial metabolite, which is found in Escherichia coli. N-Acetyl-D-Glucosamine can induce yeast-mycelial conversion in Candida albicans. N-Acetyl-D-Glucosamine also enhances healing of cartilaginous injuries in rabbits .
|
-
- HY-107535
-
|
GPR119
TRP Channel
|
Metabolic Disease
|
AS1269574 is a potent, orally available GPR119 agonist, with an EC50 of 2.5 μM in HEK293 cells expressing human GPR119. AS1269574 activates TRPA1 cation channels to stimulate glucagon-like peptide-1 (GLP-1) secretion. AS1269574 specifically induces glucose-dependent insulin secretion from pancreatic β-cells only under high-glucose conditions. AS1269574 has the potential for the research of type 2 diabetes .
|
-
- HY-B1080A
-
|
Influenza Virus
Akt
|
Infection
Metabolic Disease
Inflammation/Immunology
Cancer
|
Tilorone is an orally active antiviral agent and interferon inducer that also has potential antineoplastic, immunomodulatory, and metabolic modulating effects. Tilorone induces an abnormally delayed interferon response and primarily stimulates interferon production in lymphoid tissue. Thus, Tilorone exerts antiviral effects and can be used as a chemotherapeutic agent. Tilorone has the potential to inhibit type 2 diabetes by increasing glucose uptake in vivo and in skeletal muscle cells by enhancing Akt2/AS160 signaling and glucose transporter levels .
|
-
- HY-P5578
-
|
GCGR
|
Metabolic Disease
|
A8SGLP-1 is an orally active GLP-1 analogue that the alanine at position 8 substituted with serine. A8SGLP-1 reduces blood glucose in db/db mice without affecting its function .
|
-
- HY-13964A
-
|
GHSR
|
Metabolic Disease
|
YIL781 hydrochloride is a potent and orally active ghrelin receptor (GHSR) antagonist. YIL781 hydrochloride produces a greater improvement in glucose homeostasis in rats. YIL781 hydrochloride inhibits the calcium response induced by ghrelin with pIC50 values of 7.90 and 8.27, respectively .
|
-
- HY-15461A
-
PF-04971729 L-pyroglutamic acid
|
SGLT
|
Metabolic Disease
|
Ertugliflozin L-pyroglutamic acid (PF-04971729 L-pyroglutamic acid) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .
|
-
- HY-13964
-
|
GHSR
|
Metabolic Disease
|
YIL781 is a potent and orally active ghrelin receptor (GHSR) antagonist. YIL781 produces a greater improvement in glucose homeostasis in rats. YIL781 inhibits the calcium response induced by ghrelin with pIC50 values of 7.90 and 8.27, respectively .
|
-
- HY-10449
-
TS 071
|
SGLT
|
Metabolic Disease
|
Luseogliflozin (TS 071) is a potent, selective, orally active sodium-dependent glucose cotransporter (SGLT) 2 inhibitor, with an IC50 of 2.26 nM, about 1765-fold selectivity over SGLT1 (IC50, 3990 nM). Luseogliflozin has the protential for researching type 2 diabetes .
|
-
- HY-123797
-
|
SGLT
|
Metabolic Disease
|
KGA-2727 is a first selective, high-affinity and orally active SGLT1 inhibitor with Kis of 97.4 nM and 43.5 nM for human and rat SGLT1, respectively. The selectivity ratios (Ki for SGLT2/Ki for SGLT1) of KGA-2727 are 140 (human) and 390 (rat). KGA-2727 has antidiabetic efficacy .
|
-
- HY-101116
-
|
GCGR
|
Metabolic Disease
|
GLP-1R Antagonist 1 (compound 5d) is an orally active, CNS penetrant and non-competitive antagonist of glucagon-like peptide 1 receptor (GLP-1R), with an IC50 of 650 nM .
|
-
- HY-19687
-
CP73850
|
Aldose Reductase
|
Metabolic Disease
|
Zopolrestat (CP73850) is a potent, orally active aldose reductase (AR) inhibitor with an IC50 of 3.1 nM. Zopolrestat is used for the research of diabetic complications .
|
-
- HY-128923
-
3-Mercaptopicolinic acid hydrochloride; 3-MPA hydrochloride
|
PEPCK
|
Metabolic Disease
|
SKF-34288 (3-Mercaptopicolinic acid) hydrochloride is an orally active phosphoenolpyruvate carboxykinase (PEPCK) inhibitor (Ki: 2-9 μM). SKF-34288 hydrochloride is a potent hypoglycemic agent by inhibiting glucose synthesis. SKF-34288 hydrochloride also inhibits Asn metabolism and increases amino acids and amides .
|
-
- HY-148575
-
|
Glycosidase
|
Metabolic Disease
|
α-Glucosidase-IN-23 is an orally active α-Glucosidase inhibitor. α-Glucosidase-IN-23 decreases blood glucose by a-glucosidase inhibition with an IC50 value of 4.48 μM. α-Glucosidase-IN-23 can be used for the research of diabetes .
|
-
- HY-N0761
-
-
- HY-128574
-
|
GLUT
|
Metabolic Disease
|
GLUT4 activator 1 (Compound 26b) is an orally active glucose transporter type 4 (GLUT4) translocation activator with an EC50 of 0.14 μM. GLUT4 activator 1 has a hypoglycemic effect. GLUT4 activator 1 can be used in diabetes research .
|
-
- HY-B2099
-
1-Butylbiguanide
|
AMPK
|
Metabolic Disease
Cancer
|
Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al) .
|
-
- HY-103023
-
CLP290
1 Publications Verification
|
Potassium Channel
|
Neurological Disease
|
CLP290 is an orally available activator of the neuron-specific K +-Cl - cotransporter KCC2, displays potential for treatment of a wide range of neurological and psychiatric indications. CLP290 can significantly lower blood arginine-vasopressin (AVP) and glucose levels in STZ (HY-13753) rats .
|
-
- HY-B2099A
-
1-Butylbiguanide hydrochloride
|
AMPK
|
Cancer
|
Buformin hydrochloride (1-Butylbiguanide hydrochloride), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin hydrochloride decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin hydrochloride also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al) .
|
-
- HY-163066
-
|
Glycosidase
|
Metabolic Disease
|
α-Glucosidase-IN-44 (compound IT4) is an inhibitor of α-glucosidase with IC50 value of 2.35 μM. α-Glucosidase-IN-44 has an oral activity. α-Glucosidase-IN-44 suppresses fasting blood glucose levels in diabetic mice .
|
-
- HY-155553
-
|
GPR119
|
Metabolic Disease
|
GPR119 agonist 2 (compound 43) is an orally active GPR119 agonist. GPR119 agonist 2 shows good pharmacokinetic characteristics in rodents and can effectively improve glucose tolerance in mice and rats. GPR119 agonist 2 has the potential to study type 2 diabetes .
|
-
- HY-P5578A
-
|
GCGR
|
Metabolic Disease
|
A8SGLP-1 TFA is an orally active GLP-1 analogue that the alanine at position 8 substituted with serine. A8SGLP-1 TFA reduces blood glucose in db/db mice without affecting its function .
|
-
- HY-147678
-
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
GPR40 agonist 5 (compound I-14) is an orally active and potent GPR40 (G protein coupled receptor 40) agonist, with an EC50 of 47 nM. GPR40 agonist 5 decreases the levels of blood glucose and improves the glucose tolerance. GPR40 agonist 5 has sufficient effectiveness for the control of hyperglycemia state in type 2 diabetic mice . GPR40 agonist 5 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-139792
-
SHR117887
|
Endogenous Metabolite
|
Metabolic Disease
|
Besigliptin tosylate (SHR117887) is a DPP-4 inhibitor with activity to improve metabolic control and β-cell function. Besigliptin tosylate can effectively reduce serum DPP-4 activity and improve oral glucose tolerance. Besigliptin tosylate significantly reduces fasting blood glucose levels and improves lipid profiles in a diabetic mouse model. The effect of besigliptin tosylate is comparable to that of the known compound vildagliptin (HY-14291) at the same concentration. Besigliptin tosylate increases insulin staining of pancreatic islet cells in chronic administration, indicating improved β-cell function .
|
-
- HY-14771S
-
-
- HY-B0488
-
L631529; MK401
|
Parasite
|
Infection
|
Clorsulon (L631529; MK401) is an orally active flukicidal agent against liver flukes (Fasciola hepatica and Fasciola gigantica) infections in calves and sheep. Clorsulon is also a competitive inhibitor of both 3-phosphoglycorate and ATP andinhibits glucose utilization and acetate and propionate formation by mature Fasciola hepatica in vitro .
|
-
- HY-W012241
-
|
Endogenous Metabolite
|
Metabolic Disease
|
Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .
|
-
- HY-110173
-
|
G protein-coupled Bile Acid Receptor 1
|
Metabolic Disease
|
TC-G 1005 is a potent, selective and orally active agonist of the BA receptor Takeda G protein-coupled receptor 5 (TGR5), with EC50s of 0.72 and 6.2 nM for hTGR5 and mTGR5, respectively. TC-G 1005 can reduce glucose levels in vivo .
|
-
- HY-15461S
-
PF-04971729-d5
|
SGLT
|
Metabolic Disease
|
Ertugliflozin-d5 is the deuterium labeled Ertugliflozin . Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .
|
-
- HY-15461S1
-
PF-04971729-d9
|
SGLT
Isotope-Labeled Compounds
|
Metabolic Disease
|
Ertugliflozin-d9 is deuterated labeled Ertugliflozin (HY-15461). Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .
|
-
- HY-N7176
-
Kaempferol-3-glucuronide; Kaempferol-3-O-glucuronide
|
Interleukin Related
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Kaempferol 3-O-β-D-glucuronide (Kaempferol-3-glucuronide) is a metabolite of kaempferol that can be taken orally and has anti-inflammatory properties. Kaempferol 3-O-β-D-glucuronide can activate AKT/GSK3β phosphorylation and improve glucose metabolism .
|
-
- HY-163433
-
|
Glycosidase
|
Metabolic Disease
|
α-Glucosidase-IN-57 (Compound 10c) is a competitive and orally active α-glucosidase inhibitor with an IC50 value of 0.180 μM and a Ki of 0.15 μM. α-Glucosidase-IN-57 can reduce fasting and overall blood glucose levels in mice, and can be used for anti-diabetes research .
|
-
- HY-15461R
-
|
SGLT
|
Metabolic Disease
|
Ertugliflozin (Standard) is the analytical standard of Ertugliflozin. This product is intended for research and analytical applications. Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .
|
-
- HY-168329
-
|
G protein-coupled Bile Acid Receptor 1
|
Metabolic Disease
|
TGR5 agonist 7 (Compound 22-Na) is a gut-restricted, orally active agonist for G protein-coupled bile acid receptor TGR5 (GPBAR1 or GPR131) with an EC50 < 1 μM. TGR5 agonist 7 exhibits blood glucose lowering effect in mouse model, and can be used in diabete research .
|
-
- HY-13529
-
LY2608204; SY-004
|
Glucokinase
|
Metabolic Disease
|
Globalagliatin (LY2608204) is an orally active glucokinase (GK) activator with an EC50 of 42 nM. Globalagliatin also stimulates glucose metabolism in rat insulinoma INS1-E cells with an EC50 of 579 nM. Globalagliatin targets both pancreatic β-cells and hepatocytes. Globalagliatin is promising for research of type 2 diabetes .
|
-
- HY-153040
-
Bach1-IN-1
|
Mitochondrial Metabolism
|
Metabolic Disease
|
HPPE (compound 236) is an orally active, potential Bach1 inhibitor. Bach1 is a transcription factor of the cap'n'collar type alkaline region leucine zipper factor family (CNC-bZip) that regulates mitochondrial metabolism and reduces glucose utilization. HPPE can be used for research in psoriasis, multiple sclerosis, and COPD .
|
-
- HY-N0807R
-
|
MMP
NF-κB
JAK
Keap1-Nrf2
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Swertiamarin (Standard) is the analytical standard of Swertiamarin. This product is intended for research and analytical applications. Swertiamarin is an orally active iridoid compound with hypoglycemic, hypolipidemic, anti rheumatic and antioxidant activities, which can be used in the research of diabetes and arthritis .
|
-
- HY-N0807
-
|
MMP
NF-κB
JAK
Keap1-Nrf2
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Swertiamarin is an orally active natural product with hypoglycemic, lipid-lowering, anti-rheumatic, and antioxidant activities. Swertiamarin can regulate the levels of pro-inflammatory cytokines, MMP, and NF-κB, and promote osteoblast proliferation. Swertiamarin has antioxidant and hepatoprotective effects against carbon tetrachloride induced rat liver toxicity through the Nrf2/HO-1 pathway. Swertiamarin can attenuate inflammatory mediators by regulating JAK2/STAT3 transcription factors in adjuvant induced arthritis rats. Swertiamarin can be used in the research of diabetes and arthritis .
|
-
- HY-143312C
-
|
GLP Receptor
|
Metabolic Disease
|
(S)-V-0219 is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (S)-V-0219 activates calcium fluxes in HEK cells stably expressing hGLP-1R. (S)-V-0219 is orally active and ameliorates high glucose levels in mice and inhibits feeding behavior in fasted mice .
|
-
- HY-143312E
-
|
GLP Receptor
|
Metabolic Disease
|
(S)-V-0219 hydrochloride is an enantiomer of V-0219 (HY-143312). V-0219 is an orally active and positive allosteric modulator (PAM) of the GLP Receptor-1 (GLP-1R). (S)-V-0219 hydrochloride activates calcium fluxes in HEK cells stably expressing hGLP-1R. (S)-V-0219 hydrochloride is orally active and ameliorates high glucose levels in mice and inhibits feeding behavior in fasted mice .
|
-
- HY-W040040A
-
|
Endogenous Metabolite
|
Metabolic Disease
|
γ-Cyclodextrin hydrate is an orally active cyclic oligosaccharide composed of eight glucose molecules, which can be formed by bacteria digesting starch. γ-Cyclodextrin hydrate can form water-soluble inclusion complexes with a variety of poorly soluble compounds and is widely used in fields such as pharmacy and food. In addition, γ-Cyclodextrin hydrate has good safety .
|
-
- HY-W014078
-
|
Others
|
Metabolic Disease
|
4-(3-Methyl-5-oxo-2-pyrazolin-1-yl)benzoic acid has hypoglycaemic activity. 4-(3-Methyl-5-oxo-2-pyrazolin-1-yl)benzoic acid follows a mechanism based on the response to the oral glucose overcharge .
|
-
- HY-W040040
-
|
Endogenous Metabolite
|
Metabolic Disease
|
γ-Cyclodextrin is an orally active cyclic oligosaccharide composed of eight glucose molecules, which can be formed by bacteria digesting starch. γ-Cyclodextrin can form water-soluble inclusion complexes with a variety of poorly soluble compounds and is widely used in fields such as pharmacy and food. In addition, γ-Cyclodextrin has good safety .
|
-
- HY-B2099S
-
1-Butylbiguanide-d9 hydrochloride
|
Isotope-Labeled Compounds
AMPK
|
Metabolic Disease
Cancer
|
Buformin-d9 (hydrochloride) is the deuterium labeled Buformin. Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al) .
|
-
- HY-17638
-
DSP-3235 free base; KGA-3235 free base; GSK-1614235 free base
|
SGLT
|
Metabolic Disease
|
Mizagliflozin (DSP-3235 free base) is a potent, orally active and selective SGLT1 inhibitor, with a Ki of 27 nM for human SGLT1. Mizagliflozin displays 303-fold selectivity over SGLT2. Mizagliflozin is used as an antidiabetic agent that can modify postprandial blood glucose excursion. Mizagliflozin also exhibits potential in the amelioration of chronic constipation .
|
-
- HY-N0330
-
|
Apoptosis
Autophagy
PI3K
c-Myc
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Momordin Ic is an orally active triterpenoid saponin that can be isolated from Kochia scoparia. It is also a SUMO specific protease 1 (SENP1) inhibitor, SENP1/c-MYC signaling pathway inhibitor, and apoptosis inducer. Momordin Ic induces autophagy and apoptosis in liver cancer cells through the PI3K/Akt and MAPK signaling pathways mediated by reactive oxygen species. Momordin Ic has the ability to control glucose induced blood glucose elevation, inhibit gastric emptying, resist rheumatoid arthritis, reduce CCl4 (HY-Y0298) induced hepatotoxicity and anti-tumor activity .
|
-
- HY-14860R
-
|
Glycosidase
PI3K
|
Metabolic Disease
|
1-Deoxynojirimycin (Standard) is the analytical standard of 1-Deoxynojirimycin. This product is intended for research and analytical applications. 1-Deoxynojirimycin (Duvoglustat) is a potent and orally active α-glucosidase inhibitor. 1-Deoxynojirimycin suppresses postprandial blood glucose and is widely used for diabetes mellitus. 1-Deoxynojirimycin possesses antihyperglycemic, anti-obesity, and antiviral features .
|
-
- HY-108614
-
|
Phosphorylase
|
Metabolic Disease
|
GPi688 is a potent and orally active glycogen phosphorylase (GPa) inhibitor with IC50s of 19 nM, 61 nM and 12 nM for human liver GPa, rat liver GPa and human skeletal muscle GPa, respectively . GPi688 can inhibit glucagons-mediated glucose output in rat primary hepatocytes. GPi688 can be used for researching glucagon-mediated hyperglycaemia .
|
-
- HY-129707
-
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
AMG 837 hemicalcium is a potent, orally bioavailable and partial agonist of GPR40/FFA1. AMG 837 hemicalcium inhibits specific [ 3H]AMG 837 binding at the human FFA1 receptor with a pIC50 of 8.13. AMG 837 hemicalcium could enhance insulin secretion and lower glucose levels in rodents .
|
-
- HY-B0488R
-
|
Parasite
|
Infection
|
Clorsulon (Standard) is the analytical standard of Clorsulon. This product is intended for research and analytical applications. Clorsulon (L631529; MK401) is an orally active flukicidal agent against liver flukes (Fasciola hepatica and Fasciola gigantica) infections in calves and sheep.?Clorsulon is also a competitive inhibitor of both 3-phosphoglycorate and ATP andinhibits glucose utilization and acetate and propionate formation by mature Fasciola hepatica in vitro .
|
-
- HY-N0527
-
Penta-O-galloyl-β-D-glucose; 1,2,3,4,6-Pentagalloyl glucose
|
JAK
Keap1-Nrf2
Apoptosis
β-catenin
Reactive Oxygen Species
|
Neurological Disease
Inflammation/Immunology
Cancer
|
Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) is an orally active gallic tannin compound and an inducer of apoptosis and autophagy. Pentagalloglucose induces cell apoptosis and autophagy through the GSK3β/β-catenin pathway. Pentagalloglucose has antioxidant, anti mutagenic, anti-inflammatory, anticonvulsant, cardioprotective, anti allergic, cholesterol lowering, and anti-tumor activities .
|
-
- HY-W012241S1
-
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Metabolic Disease
|
Dodecanedioic acid-d4 is the deuterium labeled Dodecanedioic acid (HY-W012241). Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .
|
-
- HY-W011012
-
|
Adenosine Receptor
|
Metabolic Disease
|
Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes .
|
-
- HY-14806A
-
-
- HY-14399
-
CHF5074; CSP-1103
|
γ-secretase
Apoptosis
|
Neurological Disease
|
Itanapraced (CHF5074) is an orally active γ-secretase modulator and a non-steroidal anti-inflammatory derivative. Itanapraced reduces Aβ42 and Aβ40 secretion with IC50 values of 3.6 and 18.4 μM, respectively. Itanapraced inhibits cell apoptosis of hippocampal neurons induced by oxygen and glucose deprivation (OGD). Itanapraced can be used for the research of Alzheimer's disease .
|
-
- HY-14806
-
MP-513
|
Dipeptidyl Peptidase
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
|
Teneligliptin (MP-513) hydrobromide hydrate is an orally active and selective dipeptidyl peptidase 4 (DPP-4) inhibitor (IC50s: 0.37 and 0.29 nM for the human and rat DPP-4, respectively). Teneligliptin hydrobromide hydrate improves blood glucose levels and can be used in researches related to type 2 diabetes mellitus .
|
-
- HY-14806B
-
-
- HY-W012241S
-
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Metabolic Disease
|
Dodecanedioic acid-d20 is the deuterium labeled Dodecanedioic acid (HY-W012241). Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .
|
-
- HY-101292
-
|
PPAR
|
Metabolic Disease
|
FK614 is an orally active, non-thiazolidinedione (TZD) type, and selective PPARγ modulator (SPPARM). FK614 functions as a PPARγ agonist with potent anti-diabetic activity in vivo. FK614 has different effects on the activation of PPARγ at each stage of adipocyte differentiation. FK614 can be used for the research of hyperglycemia, hypertriglyceridemia, glucose intolerance and type 2 diabetes .
|
-
- HY-N0330R
-
|
Apoptosis
Autophagy
PI3K
c-Myc
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Momordin Ic (Standard) is the analytical standard of Momordin Ic. This product is intended for research and analytical applications. Momordin Ic is an orally active triterpenoid saponin that can be isolated from Kochia scoparia. It is also a SUMO specific protease 1 (SENP1) inhibitor, SENP1/c-MYC signaling pathway inhibitor, and apoptosis inducer. Momordin Ic induces autophagy and apoptosis in liver cancer cells through the PI3K/Akt and MAPK signaling pathways mediated by reactive oxygen species. Momordin Ic has the ability to control glucose induced blood glucose elevation, inhibit gastric emptying, resist rheumatoid arthritis, reduce CCl4 (HY-Y0298) induced hepatotoxicity and anti-tumor activity .
|
-
- HY-B1092A
-
D-Gluconic acid sodium salt; Sodium D-gluconate; D-Gluconate sodium salt
|
Endogenous Metabolite
NO Synthase
Interleukin Related
ERK
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
Gluconate sodium (D-Gluconic acid sodium salt) is an orally active glucose derivative. Gluconate sodium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate sodium inhibits ERK phosphorylation. Gluconate sodium has antioxidant and antiplatelet activation activities. Gluconate sodium has antitumor activity against colorectal cancer. Gluconate sodium improves osteoarthritis, intestinal damage and acute lung injury .
|
-
- HY-144267
-
|
Glucosylceramide Synthase (GCS)
|
Neurological Disease
Metabolic Disease
|
Glucosylceramide synthase-IN-2 (compound T-690) is a potent, brain-penetrant and orally active glucosylceramide synthase (GCS) inhibitor with IC50s of 15 nM and 190 nM for human GCS and mouse GCS, respectively.Glucosylceramide synthase-IN-2 exhibits noncompetitive type inhibition with C8-ceramide and UDP-glucose.Glucosylceramide synthase-IN-2 can be used for Gaucher's disease research .
|
-
- HY-W012241R
-
|
Reference Standards
Endogenous Metabolite
|
Metabolic Disease
|
Dodecanedioic acid (Standard) is the analytical standard of Dodecanedioic acid (HY-W012241). This product is intended for research and analytical applications. Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .
|
-
- HY-15344
-
|
Biochemical Assay Reagents
|
Neurological Disease
Metabolic Disease
|
Ketone monoester is an orally available ketone monoester that serves as a source of nutritional ketones. Ketone monoester increases plasma beta-hydroxybutyrate, acetoacetate, blood glucose, blood sodium, and blood creatinine levels in mouse models. Ketone monoester has the potential to improve athletic performance and endurance in animals. Ketone monoester partially prevents myasthenia in septic mice. Ketone monoester may also be used to study Parkinson's disease or diabetes .
|
-
- HY-159491
-
|
Dipeptidyl Peptidase
Glycosidase
Amylases
|
Metabolic Disease
|
DPP-4-IN-11 (compound 10) is an orally active DPP-4 inhibitor (IC50=2.75 μM) with anti-type 2 diabetes activity. DPP-4-IN-11 exerts its glucose-lowering effect by inhibiting the activities of α-glucosidase (IC50=3.02 μM) and α-amylase (IC50=3.3 μM) .
|
-
- HY-139577
-
IMB-1018972; IMB-101
|
Mitochondrial Metabolism
|
Cardiovascular Disease
Metabolic Disease
|
Ninerafaxstat (IMB-1018972) is a novel orally active cardiac mitochondrial drug that restores myocardial energy homeostasis. Ninerafaxstat competitively inhibits 3-ketoacyl-CoA thiolase (3-KAT) to partially suppress fatty acid oxidation, and shifts cardiac energy metabolism from free fatty acid oxidation to glucose oxidation, regulating myocardial substrate utilization and thereby improving cardiac efficiency. Ninerafaxstat can be used for research on cardiovascular diseases .
|
-
- HY-112584
-
6-Methoxynicotinamide
|
Amine N-methyltransferase
|
Metabolic Disease
|
JBSNF-000088 (6-Methoxynicotinamide), a analog of nicotinamide (NA), is a potent and orally active Nicotinamide N-methyltransferase (NNMT) inhibitor with IC50s of 1.8 µM, 2.8 µM, and 5.0 µM for human NNMT, monkey NNMT and mouse NNMT, respectively. JBSNF-000088 inhibits NNMT activity, reduces MNA levels and drives insulin sensitization, glucose modulation and body weight reduction in animal models of metabolic disease .
|
-
- HY-W145522
-
|
Biochemical Assay Reagents
|
Others
|
Pullulan (Pullulan standard 5800) (Mw 362-480 kDa; Mn 100-200 kDa) is a class of orally active and water-soluble linear glucosic polysaccharide. Pullulan can be isolated from the polymorphic fungus Aureobasidium pullulans. Pullulan is composed of maltotriose repeating units linked by α-1,6 linkages and is an amorphous slime matter. Pullulan is widely used in food, environment, pharmaceutical, manufacturing, and electronics .
|
-
- HY-172757
-
|
Glycosidase
|
Metabolic Disease
|
α-Glucosidase-IN-88 (Compound 3K) is an orally active and potent α-glucosidase inhibitor with an IC50 value of 6.40 µM. α-Glucosidase-IN-88 inhibits carbohydrate hydrolysis by blocking the enzyme's ability to break down glycosidic bonds, thereby reducing postprandial blood glucose levels. α-Glucosidase-IN-88 is promising for research of type 2 diabetes mellitus (T2DM) .
|
-
- HY-N0761R
-
3-Hydroxy-4-methoxycinnamic acid (Standard)
|
Adrenergic Receptor
Influenza Virus
|
Infection
Metabolic Disease
Inflammation/Immunology
Endocrinology
|
Isoferulic acid (Standard) (3-Hydroxy-4-methoxycinnamic acid (Standard)) is the analytical standard of Isoferulic acid (HY-N0761). This product is intended for research and analytical applications. Isoferulic acid (3-Hydroxy-4-methoxycinnamic acid) is an orally active cinnamic acid derivative. Isoferulic acid exhibits hypoglycemic, antiviral, and antioxidant activities. Isoferulic acid can also inhibit fructose- and glucose-mediated protein glycation. Isoferulic acid can be used in the research of diseases such as diabetes .
|
-
- HY-B2163
-
|
PPAR
Reactive Oxygen Species
STAT
NF-κB
Apoptosis
|
Cardiovascular Disease
Metabolic Disease
Cancer
|
Astaxanthin, the red dietary carotenoid, is an orally effective and potent antioxidant. Astaxanthin inhibits NF-κB and down-regulates VEGF in blood glucose. Astaxanthin exerts anti-cancer cell proliferation, increases apoptosis, impairs migration and invasion by activating PPARγ and reducing the expression of STAT3. Astaxanthin also has neuroprotective and anti-inflammatory activity and can be used in studies of cancer, diabetic retinopathy, cardiovascular disease, and in the coloring of animal feed .
|
-
- HY-155967
-
|
AMPK
Cannabinoid Receptor
|
Metabolic Disease
|
CB1R/AMPK modulator 1 (Compound 38-S) is an orally active CB1R/AMPK modulator, with an Ki of 0.81 nM and an IC50 of 3.9 nM for CB1R. CB1R/AMPK modulator 1 activates AMPK. CB1R/AMPK modulator 1 reduces food intake and body weight, and improves glucose tolerance and insulin sensitivity .
|
-
- HY-156876
-
|
Cytochrome P450
|
Metabolic Disease
|
20-HETE inhibitor-2 is an orally active 20-HETE inhibitor. 20-HETE inhibitor-2 can inhibit the activities of CYP4F2 and CYP4A11, thereby suppressing the production of 20-HETE. 20-HETE inhibitor-2 has the effect of improving blood glucose and can be used for the research of various diseases related to 20-HETE such as obesity .
|
-
- HY-N0527R
-
|
JAK
Keap1-Nrf2
Apoptosis
β-catenin
Reactive Oxygen Species
|
Neurological Disease
Inflammation/Immunology
Cancer
|
Pentagalloylglucose (Standard) is the analytical standard of Pentagalloylglucose. This product is intended for research and analytical applications. Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) is an orally active gallic tannin compound and an inducer of apoptosis and autophagy. Pentagalloglucose induces cell apoptosis and autophagy through the GSK3β/β-catenin pathway. Pentagalloglucose has antioxidant, anti mutagenic, anti-inflammatory, anticonvulsant, cardioprotective, anti allergic, cholesterol lowering, and anti-tumor activities .
|
-
- HY-B0920
-
U-17835
|
Potassium Channel
|
Metabolic Disease
Endocrinology
|
Tolazamide (U-17835) is an orally active sulfonylurea agent that inhibits sulfonylurea receptor 1 (SUR1) linked to the inwardly rectifying potassium channel (IC50 = 4.2 µM in HEK293 cells transfected with the human receptor). Tolazamide has anti-diabetic properties. Tolazamide can lower blood glucose in sulfonylurea class. Tolazamide decreases insulin dose while continuing to maintain adequate metabolic control. Tolazamide is able to improve or normalize hyperglycemia and HbA .
|
-
- HY-162703
-
|
AMPK
|
Metabolic Disease
|
Lipid-lowering agent-2 (Compound 14d) is an orally active lipid-lowering agent with an EC50 of 0.06 μM. Lipid-lowering agent-2 inhibits the lipid synthesis, activates the AMPK signaling pathway, and exhibits anti-obesity effect. Lipid-lowering agent-2 inhibits food intake, improves the glucose metabolism, and reduces the body weight and adipose tissue in high-fat diet (HFD)-induced obese mice .
|
-
- HY-171793
-
|
PPAR
|
Metabolic Disease
|
DN-108, a thiazolidinedione derivative, is an orally active peroxisome proliferator-activated receptor γ (PPARγ) agonist with antidiabetic effects. DN-108 improves hyperglycemia, hypertriglyceridemia and hyperinsulinemia in diabetic mouse models. DN-108 enhances tissue glucose uptake (e.g., increasing 2-deoxyglucose uptake in L6 muscle cells) and inhibits fatty acid synthase activity. DN-108 is promising for research of type 2 diabetes .
|
-
- HY-N2362
-
DL-2-Aminopropionic acid
|
Endogenous Metabolite
|
Metabolic Disease
|
DL-alanine, an orally active amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .
|
-
- HY-168481
-
|
GLP Receptor
|
Metabolic Disease
|
GLP-1R agonist 27 (compound 21) is a potent and orally active GLP-1R agonist. GLP-1R agonist 27 promots cyclic adenosine monophosphate (cAMP) accumulation. GLP-1R agonist 27 reduces blood glucose levels and food intake. GLP-1R agonist 27 has the potential for the research of obesity and type 2 diabetes mellitus (T2DM) .
|
-
- HY-B1350A
-
Sodium fusidate; SQ-16360
|
Bacterial
Antibiotic
Interleukin Related
|
Infection
Inflammation/Immunology
|
Fusidic acid sodium salt is an orally available antibacterial agent that inhibits bacterial protein synthesis by preventing the release of translation elongation factor G (EF-G) from ribosomes. Fusidic acid sodium salt inhibits the inhibitory and activating effects of interleukins IL-1 and IL-6 on glucose-induced insulin production and exhibits antidiabetic effects in a rat model. Fusidic acid sodium salt improves the symptoms of colitis in rats and inhibits the growth of Toxoplasma gondii and Listeria monocytogenes EGD in vitro, but not in mice .
|
-
- HY-B0481
-
BAY1099; BAY-m1099
|
Glycosidase
AMPK
Reactive Oxygen Species
|
Metabolic Disease
|
Miglitol (BAY-m1099) is an orally active antidiabetic compound that inhibits the breakdown of glycoconjugates into glucose. Miglitol inhibits glycoside hydrolase enzymes called α-glucosidases. Miglitol inhibits oxidative stress-induced apoptosis and mitochondrial ROS over-production in endothelial cells by enhancement of AMP-activated protein kinase. Dietary supplementation with Miglitol from pre-onset stage in OLETF rats delays the onset and development of diabetes and preserves the insulin secretory function of pancreatic islets .
|
-
- HY-119222
-
|
GPR109A
|
Metabolic Disease
|
GSK256073 is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC50 of 7.5 (human HCA2). GSK256073 acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM)and dyslipidemia . GPR109A: G-protein coupled receptor 109A; HCA2: hydroxy-carboxylic acid receptor 2
|
-
- HY-139577A
-
MB-1018972 trihydrochloride; IMB-101 trihydrochloride
|
Mitochondrial Metabolism
|
Cardiovascular Disease
Metabolic Disease
|
Ninerafaxstat trihydrochloride (IMB-1018972 trihydrochloride) is the trihydrochloride salt form of Ninerafaxstat (HY-139577). Ninerafaxstat trihydrochloride is a novel orally active cardiac mitochondrial drug that restores myocardial energy homeostasis. Ninerafaxstat trihydrochloride competitively inhibits 3-ketoacyl-CoA thiolase (3-KAT) to partially suppress fatty acid oxidation, and shifts cardiac energy metabolism from free fatty acid oxidation to glucose oxidation, regulating myocardial substrate utilization and thereby improving cardiac efficiency. Ninerafaxstat trihydrochloride can be used for research on cardiovascular diseases .
|
-
- HY-N0142
-
NSC 407292; RJC 02792
|
SGLT
Endogenous Metabolite
GLUT
|
Metabolic Disease
Cancer
|
Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill.,has anti-inflammatory activities. Phloridzin is a specific,competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC50values of 49 μM and 61 μM,respectively .Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation .
|
-
- HY-B0239
-
|
Antibiotic
Bacterial
HIF/HIF Prolyl-Hydroxylase
VEGFR
Autophagy
Apoptosis
Beclin1
JNK
Akt
MMP
|
Infection
Cancer
|
Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research .
|
-
- HY-119222A
-
|
GPR109A
|
Metabolic Disease
|
GSK256073 tris is a potent, selective and orally active GPR109A agonist and a long-lasting and non-flushing HCA2 full agonist with a pEC50 of 7.5 (human HCA2). GSK256073 tris acutely improves glucose homeostasis via inhibition of lipolysis and has the potential for the study of type 2 diabetes mellitus (T2DM)and dyslipidemia . GPR109A: G-protein coupled receptor 109A; HCA2: hydroxy-carboxylic acid receptor 2
|
-
- HY-W040040R
-
|
Endogenous Metabolite
|
Metabolic Disease
|
γ-Cyclodextrin (Standard) is the analytical standard of γ-Cyclodextrin (HY-W040040). This product is intended for research and analytical applications. γ-Cyclodextrin is an orally active cyclic oligosaccharide composed of eight glucose molecules, which can be formed by bacteria digesting starch. γ-Cyclodextrin can form water-soluble inclusion complexes with a variety of poorly soluble compounds and is widely used in fields such as pharmacy and food. In addition, γ-Cyclodextrin has good safety.
|
-
- HY-B1092AR
-
D-Gluconic acid sodium salt (Standard); Sodium D-gluconate (Standard); D-Gluconate sodium salt (Standard)
|
Endogenous Metabolite
|
Others
Cancer
|
Gluconate (sodium) (Standard) is the analytical standard of Gluconate (sodium). This product is intended for research and analytical applications. Gluconate sodium (D-Gluconic acid sodium salt) is an orally active glucose derivative. Gluconate sodium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate sodium inhibits ERK phosphorylation. Gluconate sodium has antioxidant and antiplatelet activation activities. Gluconate sodium has antitumor activity against colorectal cancer. Gluconate sodium improves osteoarthritis, intestinal damage and acute lung injury .
|
-
- HY-161834
-
|
Pyroptosis
Aquaporin
NOD-like Receptor (NLR)
p38 MAPK
|
Infection
Metabolic Disease
Inflammation/Immunology
|
RG100204 is a selective, orally available inhibitor of the aquaporin AQP9. RG100204 directly inhibits AQP9 channel function, preventing the transmembrane transport of water, glycerol, and H 2O 2. RG100204 reduces the activation of the NLRP3 inflammasome and p38 MAPK signaling pathways, thereby alleviating inflammation and pyroptosis. RG100204 reduces multi-organ dysfunction in a mouse sepsis model and shows glucose-regulating effects in diabetic db/db mice .
|
-
- HY-N1570
-
-
- HY-130272
-
|
Others
|
Cardiovascular Disease
|
Anti-MI/R injury agent 1 (compound 18), a Panaxatriol derivative, is an orally active, potent anti-myocardial ischemia/reperfusion (anti-MI/R) injury agent. Anti-MI/R injury agent 1 enhances oxygen-glucose deprivation and reperfusion (OGD/R)-induced cardiomyocyte injury cell viability. Anti-MI/R injury agent 1 can markedly reduce myocardial infarction size, decrease circulating cardiac troponin I (cTnI) leakage, and alleviate cardiac tissue damage in the rats .
|
-
- HY-158056
-
|
GLUT
URAT1
|
Metabolic Disease
|
URAT1/GLUT9-IN-1 (compound 29) can inhibit both uric acid transporter 1 (URAT1) (IC50=2.01 μM) and glucose transporter 9 (GLUT9) (IC50=18.21 μM). URAT1/GLUT9-IN-1 exhibits favorable pharmacokinetic properties and oral bioavailability. URAT1/GLUT9-IN-1 can be uesd for gout and hyperuricemia research .
|
-
- HY-N2181
-
|
Cytochrome P450
Apoptosis
Bacterial
Autophagy
|
Infection
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
Acetylshikonin is an oral active anti-cancer, anti-inflammatory, antioxidant, anti-fertility, antibacterial, and neuroprotective agent. Acetylshikonin is a inhibitor of acetylcholinase (AChE) (IC50=34.6 μM) and nonselective cytochrome P450. Acetylshikonin can induce Apoptosis and Autophagy in cancer cells. Acetylshikonin regulates blood glucose, liver fat metabolism, and renal fibrosis, and is used in the study of diabetes, diabetic nephropathy (DN), obesity, and nonalcoholic fatty liver disease (NAFLD) .
|
-
- HY-14806S2
-
-
- HY-W014901
-
BPF; 4,4'-Dihydroxydiphenylmethane
|
Reactive Oxygen Species
Akt
GSK-3
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Endocrinology
|
Bisphenol F is an orally active endocrine disruptor. Bisphenol F promotes ROS generation, upregulates p-AKT/p-GSK3β, and induces Apoptosis. Bisphenol F interferes with glucose metabolism, affects neurodevelopment and reproductive function. Bisphenol F reduces social novelty preference in mouse offspring. Bisphenol F can be used in bone, blood, and fat-related studies. Bisphenol F is used as a substitute for Bisphenol A (HY-18260) .
|
-
- HY-168049
-
|
PPAR
Akt
|
Metabolic Disease
|
ZLY06 is an orally active dual agonist of peroxisome proliferator-activated receptor (PPAR) δ and γ (PPAR δ: EC50=341 nM; PPAR γ: EC50=237 nM). ZLY06 induces hepatic lipid accumulation by inhibiting the phosphorylation of AKT1, mediating the upregulation of CD36. In addition, ZLY06 significantly improves glucose and lipid metabolism without increasing body weight, and alleviates fatty liver by promoting β-oxidation of fatty acids and inhibiting hepatic lipogenesis .
|
-
- HY-N0457
-
Cichoric acid; Dicaffeoyltartaric acid
|
Reactive Oxygen Species
Apoptosis
|
Metabolic Disease
Inflammation/Immunology
|
Chicoric acid (Cichoric acid), an orally active dicaffeyltartaric acid, induces reactive oxygen species (ROS) generation. Chicoric acid inhibits cell viability and induces mitochondria-dependent apoptosis in 3T3-L1 preadipocytes through ROS-mediated PI3K/Akt and MAPK signaling pathways. Chicoric acid increases glucose uptake, improves insulin resistance, and attenuates glucosamine-induced inflammation. Chicoric acid has antidiabetic properties and antioxidant, anti-inflammatory effects .
|
-
- HY-W011012S
-
|
Isotope-Labeled Compounds
|
Others
|
Adenosine 5'-monophosphate- 13C (disodium) is a 13C-labeled Adenosine 5'-monophosphate (HY-W011012). Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes .
|
-
- HY-13755
-
Sulforaphane
Maximum Cited Publications
50 Publications Verification
|
HDAC
Keap1-Nrf2
Apoptosis
Bcl-2 Family
Caspase
Reactive Oxygen Species
|
Inflammation/Immunology
Cancer
|
Sulforaphane is an orally active inducer of the Keap1/Nrf2/ARE pathway. Sulforaphane promotes the transcription of tumor-suppressing proteins and effectively inhibits the activity of HDACs. Through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1 expression, Sulforaphane protects the heart. Sulforaphane suppresses high glucose-induced pancreatic cancer through AMPK-dependent signal transmission. Sulforaphane exhibits both anticancer and anti-inflammatory properties .
|
-
- HY-B0239R
-
|
Antibiotic
Bacterial
HIF/HIF Prolyl-Hydroxylase
VEGFR
Autophagy
Apoptosis
Beclin1
JNK
Akt
MMP
|
Infection
Cancer
|
Chloramphenicol (Standard) is the analytical standard of Chloramphenicol. This product is intended for research and analytical applications. Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research .
|
-
- HY-W011012S1
-
|
Isotope-Labeled Compounds
|
Others
|
Adenosine 5'-monophosphate-d2 disodium is the deuterium labeled Adenosine 5'-monophosphate (HY-W011012). Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes .
|
-
- HY-135359R
-
|
Drug Metabolite
|
Neurological Disease
|
Adenosine 5'-monophosphate (disodium) (Standard) is the analytical standard of Adenosine 5'-monophosphate (disodium). This product is intended for research and analytical applications. Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes .
|
-
- HY-B0920R
-
U-17835 (Standard)
|
Reference Standards
Potassium Channel
|
Metabolic Disease
Endocrinology
|
Tolazamide (U-17835) (Standard) is the analytical standard of Tolazamide. This product is intended for research and analytical applications. Tolazamide is an orally active sulfonylurea agent that inhibits sulfonylurea receptor 1 (SUR1) linked to the inwardly rectifying potassium channel (IC50 = 4.2 µM in HEK293 cells transfected with the human receptor). Tolazamide has anti-diabetic properties. Tolazamide can lower blood glucose in sulfonylurea class. Tolazamide decreases insulin dose while continuing to maintain adequate metabolic control. Tolazamide is able to improve or normalize hyperglycemia and HbA .
|
-
- HY-19522C
-
MBX-8025 Lysine dihydrate; RWJ-800025 Lysine dihydrate
|
PPAR
|
Metabolic Disease
|
Seladelpar (MBX-8025) Lysine dihydrate is the Lysine dihydrate salt form of Seladelpar (HY-19522). Seladelpar Lysine dihydrate is an orally active agonist for potent PPAR-δ, with EC50 of 2 nM. Seladelpar Lysine dihydrate shows more than 750-fold and 2500-fold selectivity over the PPARα and PPARγ receptors, respectively. Seladelpar Lysine dihydrate can be used for the study of primary biliary cholangitis. Seladelpar Lysine dihydrate normalizes hyperglycemia, hyperinsulinemia, glucose, serum lipids and cholesterol levels, ameliorates the nonalcoholic steatohepatitis in mouse model .
|
-
- HY-13967B
-
|
Free Fatty Acid Receptor
|
Metabolic Disease
|
AMG 837 calcium hydrate is a potent, orally bioavailable and partial agonist of GPR40/FFA1. AMG 837 calcium hydrate inhibits specific [ 3H]AMG 837 binding at the human FFA1 receptor with a pIC50 of 8.13. AMG 837 calcium hydrate could enhance insulin secretion and lower glucose levels in rodents . AMG 837 (calcium hydrate) is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-N10612
-
|
AMPK
PPAR
TRP Channel
Mitochondrial Metabolism
|
Metabolic Disease
Cancer
|
Petasin inhibits adipogenesis in cell 3T3-F442A with an IC50 of 0.95 μM. Petasin inhibits the expression of lipid synthesis factors ACC1, FAS and SCD1 by inhibiting transcription factors PPARγ and C/EBPα, as well as targeting TRPA1 and TRPV1 channels . Petasin inhibits mitochondrial complex I, thereby inhibiting tumor growth and metastasis. Petasin activates AMPK signaling pathway, participating in regulation of glucose and lipid metabolism. Petasin is orally active .
|
-
- HY-W011012R
-
|
Adenosine Receptor
|
Metabolic Disease
|
Adenosine 5'-monophosphate (disodium) (Standard) is the analytical standard of Adenosine 5'-monophosphate (disodium). This product is intended for research and analytical applications. Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes .
|
-
- HY-B0239S2
-
|
JNK
Apoptosis
VEGFR
MMP
Bacterial
Akt
Autophagy
HIF/HIF Prolyl-Hydroxylase
Antibiotic
Beclin1
|
Cancer
|
Threo-Chloramphenicol-d6 is the deuterium labeled Chloramphenicol . Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research .
|
-
- HY-134816
-
|
Toll-like Receptor (TLR)
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
D-Glucan is an orally effective Dectin-1 receptor immune activator with antioxidant properties (reducing TNF-α). D-Glucan activates macrophages and neutrophils to scavenge free radicals, inhibit oxidative stress and inflammatory responses, and improve insulin sensitivity. D-Glucan promotes glycolysis by enhancing the activity of the antioxidant enzyme glutathione, inhibiting gluconeogenesis and activating GK. D-Glucan can be used in the research of liver damage protection (antagonizing Acetaminophen (HY-66005) toxicity), radiation protection (synergistic with vitamin E) and diabetes (improving glucose metabolism) .
|
-
- HY-N8518
-
|
Phospholipase
p38 MAPK
Apoptosis
NF-κB
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Malabaricone C is an orally active and noncompetitive sphingomyelin synthase (SMS) inhibitor with IC50 values of 3 μM and 1.5 μM for SMS 1 and SMS 2, respectively. Malabaricone C reduces body weight gain, improves glucose tolerance, and decreases lipid accumulation in the liver, showing significant prevention of high fat diet-induced fatty liver in mice. Malabaricone C has anti-inflammatory effects, which is found in the fruits of Myristica cinnamomea King. Malabaricone C is promising for research of obesity and immunological disorders caused due to hyper-activation of T-cells .
|
-
- HY-N0142R
-
NSC 407292 (Standard); RJC 02792 (Standard)
|
SGLT
Endogenous Metabolite
GLUT
|
Metabolic Disease
Cancer
|
Phloretin (Standard) is the analytical standard of Phloretin. This product is intended for research and analytical applications. Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill., has anti-inflammatory activities. Phloridzin is a specific, competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC50values of 49 μM and 61 μM, respectively .Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation .
|
-
- HY-N5027
-
Oxyberberin; Berlambine; 8-Oxoberberine
|
Others
|
Infection
Neurological Disease
Inflammation/Immunology
|
Oxyberberine (Oxyberberin; Berlambine) is an orally effective heme oxygenase HO-1 agonist that can activate antioxidant mechanisms by regulating the PI3K/Akt/AMPK signaling pathway. Oxyberberine induces HO-1 expression, increases SOD and GSH-Px activity, inhibits NF-κB-mediated inflammatory responses, and improves insulin sensitivity and glucose metabolism. Oxyberberine has anti-diabetic, neuroprotective, anti-inflammatory and antioxidant effects, and can be used to study type 2 diabetes, traumatic brain injury (TBI) and inflammatory bowel disease .
|
-
- HY-N0457R
-
|
Reactive Oxygen Species
Apoptosis
|
Metabolic Disease
Inflammation/Immunology
|
Chicoric acid (Standard) is the analytical standard of Chicoric acid. This product is intended for research and analytical applications. Chicoric acid (Cichoric acid), an orally active dicaffeyltartaric acid, induces reactive oxygen species (ROS) generation. Chicoric acid inhibits cell viability and induces mitochondria-dependent apoptosis in 3T3-L1 preadipocytes through ROS-mediated PI3K/Akt and MAPK signaling pathways. Chicoric acid increases glucose uptake, improves insulin resistance, and attenuates glucosamine-induced inflammation. Chicoric acid has antidiabetic properties and antioxidant, anti-inflammatory effects .
|
-
- HY-173115
-
|
COX
Lipoxygenase
Interleukin Related
PPAR
|
Metabolic Disease
Inflammation/Immunology
|
15-LOX-IN-2 (Compound 2a) is an orally active COX-2/15-LOX inhibitor and a partial agonist of PPARγ. 15-LOX-IN-2 has anti-inflammatory activity and inhibits the levels of 20-HETE, IL-1β and TNF-α in RAW 264.7 cells treated with LPS (HY-D1056). In addition, 15-LOX-IN-2 has significant glucose uptake capacity in the absence of insulin. 15-LOX-IN-2 can be used for the research of metabolic diseases .
|
-
- HY-W145521
-
β Glucan
|
Biochemical Assay Reagents
IKK
NO Synthase
Bacterial
|
Infection
Inflammation/Immunology
Cancer
|
β-1,3-Glucan (β Glucan) is an orally active polysaccharide composed of glucose polymers. β-1,3-Glucan increase the activity of IKKβ kinase, enhances the production of nitric oxide. β-1,3-Glucan improves resistance to Vibrio harveyi infection. β-1,3-Glucan enhances immune response, promotes blood pressure recovery, reduces lung, kidney and liver damage, inhibits the growth of syngeneic tumors .
|
-
- HY-W014901S1
-
BPF-13C12; 4,4'-Dihydroxydiphenylmethane-13C12
|
Isotope-Labeled Compounds
Reactive Oxygen Species
Akt
GSK-3
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Endocrinology
|
Bisphenol F- 13C12 is the 13C labeled Bisphenol F (HY-W014901). Bisphenol F is an orally active endocrine disruptor. Bisphenol F promotes ROS generation, upregulates p-AKT/p-GSK3β, and induces Apoptosis. Bisphenol F interferes with glucose metabolism, affects neurodevelopment and reproductive function. Bisphenol F reduces social novelty preference in mouse offspring. Bisphenol F can be used in bone, blood, and fat-related studies. Bisphenol F is used as a substitute for Bisphenol A (HY-18260) .
|
-
- HY-W014901S
-
BPF-13C6; 4,4'-Dihydroxydiphenylmethane-13C6
|
Isotope-Labeled Compounds
Reactive Oxygen Species
Akt
GSK-3
Apoptosis
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Endocrinology
|
Bisphenol F- 13C6 is the 13C labeled Bisphenol F (HY-W014901). Bisphenol F is an orally active endocrine disruptor. Bisphenol F promotes ROS generation, upregulates p-AKT/p-GSK3β, and induces Apoptosis. Bisphenol F interferes with glucose metabolism, affects neurodevelopment and reproductive function. Bisphenol F reduces social novelty preference in mouse offspring. Bisphenol F can be used in bone, blood, and fat-related studies. Bisphenol F is used as a substitute for Bisphenol A (HY-18260) .
|
-
- HY-N10319
-
|
Epigenetic Reader Domain
Necroptosis
TRP Channel
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Artepillin C is an orally active CREB/CRTC2 inhibitor and TRPA1 covalent agonist (EC50=1.8 μM). Artepillin C inhibits CREB/CRTC2-mediated gene transcription and downregulates BMAL1 expression to regulate glucose and lipid metabolism. Artepillin C can also activate TRPA1 channels to induce spicy taste signals. Artepillin C can inhibit tumor cell proliferation, induce necroptosis, improve insulin resistance and inhibit liver lipid synthesis. Artepillin C can be used in the study of metabolic syndrome, tumor prevention and treatment, and inflammation .
|
-
- HY-W014901R
-
BPF (Standard); 4,4'-Dihydroxydiphenylmethane (Standard)
|
Reference Standards
Reactive Oxygen Species
Akt
GSK-3
Apoptosis
|
Neurological Disease
Metabolic Disease
Endocrinology
|
Bisphenol F (Standard) is the analytical standard of Bisphenol F (HY-W014901). This product is intended for research and analytical applications. Bisphenol F is an orally active endocrine disruptor. Bisphenol F promotes ROS generation, upregulates p-AKT/p-GSK3β, and induces Apoptosis. Bisphenol F interferes with glucose metabolism, affects neurodevelopment and reproductive function. Bisphenol F reduces social novelty preference in mouse offspring. Bisphenol F can be used in bone, blood, and fat-related studies. Bisphenol F is used as a substitute for Bisphenol A (HY-18260) .
|
-
- HY-N2362S8
-
DL-2-Aminopropionic acid-d7
|
Isotope-Labeled Compounds
|
Metabolic Disease
|
DL-Alanine-d7 (DL-2-Aminopropionic acid-d7) is deuterium labeled DL-Alanine. DL-alanine, an orally active amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .
|
-
- HY-146468
-
|
Dipeptidyl Peptidase
GPR119
Potassium Channel
|
Metabolic Disease
|
DPP-4/GPR119 modulator 1 (Compound 22) is an orally active dipeptidyl peptidase IV (DPP-IV) inhibitor and GPR119 agonist. DPP-4/GPR119 modulator 1 shows blood glucose-lowering effect and moderate inhibition on hERG channel with an IC50 of 4.9 μM. DPP-4/GPR119 modulator 1 can be used for diabetes research . DPP-4/GPR119 modulator 1 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
|
-
- HY-N2362S9
-
DL-2-Aminopropionic acid-13C2,15N2
|
Isotope-Labeled Compounds
Endogenous Metabolite
|
Metabolic Disease
|
DL-Alanine- 13C2, 15N (DL-2-Aminopropionic acid- 13C2, 15N) is 13C and 15N labeled DL-Alanine. DL-alanine, an orally active amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .
|
-
- HY-116673
-
|
Histone Acetyltransferase
|
Neurological Disease
|
TTK21 is an activator of the histone acetyltransferases CBP/p300. TTK21 passes the blood–brain barrier, induces no toxicity, and reaches different parts of the brain when conjugated to glucose-based carbon nanosphere (CSP). TTK21 has beneficial implications for the brain functions of neurogenesis and long-term memory .CSP-TTK21 can ameliorate Aβ-impaired long-term potentiation (LTP). CSP-TTK21 may enhance the transcription of genes that promote synaptic health and cognitive function . CSP-TTK21 is orally effective and leads to improvements in motor functions, histone acetylation dynamics in a spinal injury rat model .
|
-
- HY-173479
-
|
GLP Receptor
|
Cardiovascular Disease
Metabolic Disease
|
GLP-1R agonist 30 is a selective and orally active GLP-1R agonist with an EC50 of 0.048 nM. GLP-1R has excellent selectivity, with EC50 greater than 20 μM for GLP-2R, GIPR, and GCPR. GLP-1R agonist significantly increases cAMP-stimulating activity while markedly reducing hERG inhibitory activities. GLP-1R agonist has preferable absorption and excellent β-arrestin pathway selectivity. GLP-1R agonist effectively improves glucose tolerance and promoted insulin secretion in B-hGLP1R knock-in mice .
|
-
- HY-N2468
-
1,4-β-D-Xylobiose; 1,4-D-Xylobiose
|
TNF Receptor
Claudin
HSP
|
Metabolic Disease
Inflammation/Immunology
|
Xylobiose (1,4-β-D-Xylobiose; 1,4-D-Xylobiose) is an orally active Claudin 2/CLDN2 inhibitor and HSP27 inducer. Xylobiose works by regulating intestinal barrier function and glucose and lipid metabolism-related signaling pathways. Xylobiose inhibits CLDN2 expression to reduce intestinal permeability, induces HSP27 to enhance cell protection, and regulates the miR-122a/miR-33a axis to inhibit liver lipid synthesis and improve insulin resistance. Xylobiose can strengthen intestinal barrier integrity, reduce blood sugar and blood lipid levels, and reduce oxidative stress and inflammatory response. Xylobiose can be used in the study of type 2 diabetes and metabolic syndrome .
|
-
- HY-N10319R
-
|
Reference Standards
TRP Channel
Necroptosis
Epigenetic Reader Domain
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
Artepillin C (Standard) is the analytical standard of Artepillin C (HY-N10319). This product is intended for research and analytical applications. Artepillin C is an orally active CREB/CRTC2 inhibitor and TRPA1 covalent agonist (EC50=1.8 μM). Artepillin C inhibits CREB/CRTC2-mediated gene transcription and downregulates BMAL1 expression to regulate glucose and lipid metabolism. Artepillin C can also activate TRPA1 channels to induce spicy taste signals. Artepillin C can inhibit tumor cell proliferation, induce apoptosis, improve insulin resistance and inhibit liver lipid synthesis. Artepillin C can be used in the study of metabolic syndrome, tumor prevention and treatment, and inflammation .
|
-
- HY-N7075
-
Inulin
2 Publications Verification
|
Endogenous Metabolite
|
Metabolic Disease
Cancer
|
Inulin is an orally active prebiotic targeting the intestinal microbiota, selectively promoting the proliferation and activity of beneficial bacteria such as bifidobacteria and lactic acid bacteria, and playing a role in regulating the intestinal microecology. The functions of Inulin include: ① Fermentation by probiotics in the colon to produce short-chain fatty acids (such as butyrate and propionate), lowering the intestinal pH and inhibiting the overgrowth of harmful bacteria; ② Enhancing the intestinal barrier function and reducing endotoxin translocation; ③ Directly scavenging free radicals (such as superoxide free radicals, hydroxyl free radicals) and activating antioxidant enzymes (SOD, CAT) to reduce oxidative stress. Inulin can also be used in the study of intestinal diseases (constipation, IBD), metabolic syndrome (diabetes, obesity) and liver damage by regulating glucose and lipid metabolism (such as reducing triglycerides, improving insulin sensitivity) and immune response (enhancing NK cell activity, inhibiting inflammatory factors)[1][2][3][4].
|
-
Cat. No. |
Product Name |
Type |
-
- HY-W011012
-
|
Enzyme Substrates
|
Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes .
|
-
- HY-W145522
-
|
Carbohydrates
|
Pullulan (Pullulan standard 5800) (Mw 362-480 kDa; Mn 100-200 kDa) is a class of orally active and water-soluble linear glucosic polysaccharide. Pullulan can be isolated from the polymorphic fungus Aureobasidium pullulans. Pullulan is composed of maltotriose repeating units linked by α-1,6 linkages and is an amorphous slime matter. Pullulan is widely used in food, environment, pharmaceutical, manufacturing, and electronics .
|
-
- HY-134816
-
|
Carbohydrates
|
D-Glucan is an orally effective Dectin-1 receptor immune activator with antioxidant properties (reducing TNF-α). D-Glucan activates macrophages and neutrophils to scavenge free radicals, inhibit oxidative stress and inflammatory responses, and improve insulin sensitivity. D-Glucan promotes glycolysis by enhancing the activity of the antioxidant enzyme glutathione, inhibiting gluconeogenesis and activating GK. D-Glucan can be used in the research of liver damage protection (antagonizing Acetaminophen (HY-66005) toxicity), radiation protection (synergistic with vitamin E) and diabetes (improving glucose metabolism) .
|
-
- HY-W145521
-
β Glucan
|
Carbohydrates
|
β-1,3-Glucan (β Glucan) is an orally active polysaccharide composed of glucose polymers. β-1,3-Glucan increase the activity of IKKβ kinase, enhances the production of nitric oxide. β-1,3-Glucan improves resistance to Vibrio harveyi infection. β-1,3-Glucan enhances immune response, promotes blood pressure recovery, reduces lung, kidney and liver damage, inhibits the growth of syngeneic tumors .
|
-
- HY-W040040A
-
|
Biochemical Assay Reagents
|
γ-Cyclodextrin hydrate is an orally active cyclic oligosaccharide composed of eight glucose molecules, which can be formed by bacteria digesting starch. γ-Cyclodextrin hydrate can form water-soluble inclusion complexes with a variety of poorly soluble compounds and is widely used in fields such as pharmacy and food. In addition, γ-Cyclodextrin hydrate has good safety .
|
-
- HY-W011012R
-
|
Enzyme Substrates
|
Adenosine 5'-monophosphate (disodium) (Standard) is the analytical standard of Adenosine 5'-monophosphate (disodium). This product is intended for research and analytical applications. Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes .
|
Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P5578
-
|
GCGR
|
Metabolic Disease
|
A8SGLP-1 is an orally active GLP-1 analogue that the alanine at position 8 substituted with serine. A8SGLP-1 reduces blood glucose in db/db mice without affecting its function .
|
-
- HY-P5578A
-
|
GCGR
|
Metabolic Disease
|
A8SGLP-1 TFA is an orally active GLP-1 analogue that the alanine at position 8 substituted with serine. A8SGLP-1 TFA reduces blood glucose in db/db mice without affecting its function .
|
Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-109500
-
-
-
- HY-N2486
-
-
-
- HY-N7912
-
-
-
- HY-N0936
-
-
-
- HY-N9386
-
-
-
- HY-14860A
-
-
-
- HY-14860
-
-
-
- HY-N12353
-
-
-
- HY-N2486R
-
-
-
- HY-N11551
-
-
-
- HY-A0132
-
-
-
- HY-N0761
-
-
-
- HY-W012241
-
-
-
- HY-N7176
-
-
-
- HY-N0807R
-
-
-
- HY-N0807
-
-
-
- HY-W040040A
-
-
-
- HY-W040040
-
-
-
- HY-N0330
-
-
-
- HY-14860R
-
-
-
- HY-N0527
-
Penta-O-galloyl-β-D-glucose; 1,2,3,4,6-Pentagalloyl glucose
|
Infection
Structural Classification
other families
Classification of Application Fields
Anti-aging
Source classification
Phenols
Polyphenols
Plants
Disease Research Fields
|
JAK
Keap1-Nrf2
Apoptosis
β-catenin
Reactive Oxygen Species
|
Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) is an orally active gallic tannin compound and an inducer of apoptosis and autophagy. Pentagalloglucose induces cell apoptosis and autophagy through the GSK3β/β-catenin pathway. Pentagalloglucose has antioxidant, anti mutagenic, anti-inflammatory, anticonvulsant, cardioprotective, anti allergic, cholesterol lowering, and anti-tumor activities .
|
-
-
- HY-N0330R
-
|
Kochia scoparia L. Schrad.
Triterpenes
Structural Classification
Terpenoids
Source classification
Plants
Chenopodiaceae
|
Apoptosis
Autophagy
PI3K
c-Myc
|
Momordin Ic (Standard) is the analytical standard of Momordin Ic. This product is intended for research and analytical applications. Momordin Ic is an orally active triterpenoid saponin that can be isolated from Kochia scoparia. It is also a SUMO specific protease 1 (SENP1) inhibitor, SENP1/c-MYC signaling pathway inhibitor, and apoptosis inducer. Momordin Ic induces autophagy and apoptosis in liver cancer cells through the PI3K/Akt and MAPK signaling pathways mediated by reactive oxygen species. Momordin Ic has the ability to control glucose induced blood glucose elevation, inhibit gastric emptying, resist rheumatoid arthritis, reduce CCl4 (HY-Y0298) induced hepatotoxicity and anti-tumor activity .
|
-
-
- HY-B1092A
-
-
-
- HY-W012241R
-
|
Structural Classification
Ketones, Aldehydes, Acids
Source classification
Endogenous metabolite
|
Reference Standards
Endogenous Metabolite
|
Dodecanedioic acid (Standard) is the analytical standard of Dodecanedioic acid (HY-W012241). This product is intended for research and analytical applications. Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .
|
-
-
- HY-N0761R
-
-
-
- HY-B2163
-
-
-
- HY-N0527R
-
|
Structural Classification
other families
Source classification
Phenols
Polyphenols
Plants
|
JAK
Keap1-Nrf2
Apoptosis
β-catenin
Reactive Oxygen Species
|
Pentagalloylglucose (Standard) is the analytical standard of Pentagalloylglucose. This product is intended for research and analytical applications. Pentagalloylglucose (Penta-O-galloyl-β-D-glucose) is an orally active gallic tannin compound and an inducer of apoptosis and autophagy. Pentagalloglucose induces cell apoptosis and autophagy through the GSK3β/β-catenin pathway. Pentagalloglucose has antioxidant, anti mutagenic, anti-inflammatory, anticonvulsant, cardioprotective, anti allergic, cholesterol lowering, and anti-tumor activities .
|
-
-
- HY-N2362
-
-
-
- HY-B1350A
-
-
-
- HY-N0142
-
-
-
- HY-B0239
-
-
-
- HY-B1092AR
-
D-Gluconic acid sodium salt (Standard); Sodium D-gluconate (Standard); D-Gluconate sodium salt (Standard)
|
Structural Classification
other families
Source classification
Plants
Endogenous metabolite
Saccharides
Monosaccharides
|
Endogenous Metabolite
|
Gluconate (sodium) (Standard) is the analytical standard of Gluconate (sodium). This product is intended for research and analytical applications. Gluconate sodium (D-Gluconic acid sodium salt) is an orally active glucose derivative. Gluconate sodium reduces nitric oxide and inflammatory cytokines (IL-1β and IL-6). Gluconate sodium inhibits ERK phosphorylation. Gluconate sodium has antioxidant and antiplatelet activation activities. Gluconate sodium has antitumor activity against colorectal cancer. Gluconate sodium improves osteoarthritis, intestinal damage and acute lung injury .
|
-
-
- HY-N1570
-
-
-
- HY-N2181
-
|
Quinones
Structural Classification
Classification of Application Fields
Source classification
Phenols
Polyphenols
Plants
Lithospermum erythrorhizon Sieb. et Zucc.
Naphthalene Quinones
Boraginaceae
Inflammation/Immunology
Disease Research Fields
|
Cytochrome P450
Apoptosis
Bacterial
Autophagy
|
Acetylshikonin is an oral active anti-cancer, anti-inflammatory, antioxidant, anti-fertility, antibacterial, and neuroprotective agent. Acetylshikonin is a inhibitor of acetylcholinase (AChE) (IC50=34.6 μM) and nonselective cytochrome P450. Acetylshikonin can induce Apoptosis and Autophagy in cancer cells. Acetylshikonin regulates blood glucose, liver fat metabolism, and renal fibrosis, and is used in the study of diabetes, diabetic nephropathy (DN), obesity, and nonalcoholic fatty liver disease (NAFLD) .
|
-
-
- HY-W014901
-
-
-
- HY-N0457
-
-
-
- HY-13755
-
-
-
- HY-B0239R
-
-
-
- HY-N10612
-
|
Structural Classification
Natural Products
Plants
Compositae
Piptadenia Benth.
|
AMPK
PPAR
TRP Channel
Mitochondrial Metabolism
|
Petasin inhibits adipogenesis in cell 3T3-F442A with an IC50 of 0.95 μM. Petasin inhibits the expression of lipid synthesis factors ACC1, FAS and SCD1 by inhibiting transcription factors PPARγ and C/EBPα, as well as targeting TRPA1 and TRPV1 channels . Petasin inhibits mitochondrial complex I, thereby inhibiting tumor growth and metastasis. Petasin activates AMPK signaling pathway, participating in regulation of glucose and lipid metabolism. Petasin is orally active .
|
-
-
- HY-N8518
-
-
-
- HY-N0142R
-
-
-
- HY-N5027
-
-
-
- HY-N0457R
-
|
Structural Classification
other families
Source classification
Other Phenylpropanoids
Phenols
Polyphenols
Phenylpropanoids
Plants
|
Reactive Oxygen Species
Apoptosis
|
Chicoric acid (Standard) is the analytical standard of Chicoric acid. This product is intended for research and analytical applications. Chicoric acid (Cichoric acid), an orally active dicaffeyltartaric acid, induces reactive oxygen species (ROS) generation. Chicoric acid inhibits cell viability and induces mitochondria-dependent apoptosis in 3T3-L1 preadipocytes through ROS-mediated PI3K/Akt and MAPK signaling pathways. Chicoric acid increases glucose uptake, improves insulin resistance, and attenuates glucosamine-induced inflammation. Chicoric acid has antidiabetic properties and antioxidant, anti-inflammatory effects .
|
-
-
- HY-N10319
-
-
-
- HY-W014901R
-
BPF (Standard); 4,4'-Dihydroxydiphenylmethane (Standard)
|
Orchidaceae
Galeola faberi Rolfe
Source classification
Phenols
Polyphenols
Plants
|
Reference Standards
Reactive Oxygen Species
Akt
GSK-3
Apoptosis
|
Bisphenol F (Standard) is the analytical standard of Bisphenol F (HY-W014901). This product is intended for research and analytical applications. Bisphenol F is an orally active endocrine disruptor. Bisphenol F promotes ROS generation, upregulates p-AKT/p-GSK3β, and induces Apoptosis. Bisphenol F interferes with glucose metabolism, affects neurodevelopment and reproductive function. Bisphenol F reduces social novelty preference in mouse offspring. Bisphenol F can be used in bone, blood, and fat-related studies. Bisphenol F is used as a substitute for Bisphenol A (HY-18260) .
|
-
-
- HY-N2468
-
-
-
- HY-N10319R
-
-
-
- HY-N7075
-
Inulin
2 Publications Verification
|
Structural Classification
Human Gut Microbiota Metabolites
Polysaccharides
Classification of Application Fields
Source classification
Metabolic Disease
Plants
Compositae
Endogenous metabolite
Disease Research Fields
Saccharides
Sophora tomentosa L.
|
Endogenous Metabolite
|
Inulin is an orally active prebiotic targeting the intestinal microbiota, selectively promoting the proliferation and activity of beneficial bacteria such as bifidobacteria and lactic acid bacteria, and playing a role in regulating the intestinal microecology. The functions of Inulin include: ① Fermentation by probiotics in the colon to produce short-chain fatty acids (such as butyrate and propionate), lowering the intestinal pH and inhibiting the overgrowth of harmful bacteria; ② Enhancing the intestinal barrier function and reducing endotoxin translocation; ③ Directly scavenging free radicals (such as superoxide free radicals, hydroxyl free radicals) and activating antioxidant enzymes (SOD, CAT) to reduce oxidative stress. Inulin can also be used in the study of intestinal diseases (constipation, IBD), metabolic syndrome (diabetes, obesity) and liver damage by regulating glucose and lipid metabolism (such as reducing triglycerides, improving insulin sensitivity) and immune response (enhancing NK cell activity, inhibiting inflammatory factors)[1][2][3][4].
|
-
Cat. No. |
Product Name |
Chemical Structure |
-
- HY-W012241S1
-
|
Dodecanedioic acid-d4 is the deuterium labeled Dodecanedioic acid (HY-W012241). Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .
|
-
-
- HY-W012241S
-
|
Dodecanedioic acid-d20 is the deuterium labeled Dodecanedioic acid (HY-W012241). Dodecanedioic acid is an orally active straight-chain dicarboxylic acid. As an alternative energy substrate between lipids and carbohydrates, Dodecanedioic acid can be rapidly oxidized during exercise, reducing muscle fatigue without stimulating insulin secretion. Dodecanedioic acid also exhibits blood glucose-lowering activity in non-insulin-dependent diabetes mellitus .
|
-
-
- HY-A0132S14
-
|
N-Acetyl-D-glucosamine-d3 (N-Acetyl-2-amino-2-deoxy-D-glucose-d3) is deuterium labeled N-Acetyl-D-glucosamine. N-Acetyl-D-Glucosamine (N-Acetyl-2-amino-2-deoxy-D-glucose), the D isomer of N-acetylglucosamine, is an orally active monosaccharide derivative of glucose with anti-tumor and anti-inflammation properties. N-Acetyl-D-Glucosamine is also a bacterial metabolite, which is found in Escherichia coli. N-Acetyl-D-Glucosamine can induce yeast-mycelial conversion in Candida albicans. N-Acetyl-D-Glucosamine also enhances healing of cartilaginous injuries in rabbits .
|
-
-
- HY-14771S
-
|
Imeglimin-d3 (EMD 387008-d3) is deuterium labeled Imeglimin. Imeglimin (EMD 387008) is an oral glucose-lowering agent. Imeglimin improves insulin sensitivity. Imeglimin also reduces reactive oxygen species (ROS) production, increases mitochondrial DNA and improves mitochondrial function .
|
-
-
- HY-15461S
-
|
Ertugliflozin-d5 is the deuterium labeled Ertugliflozin . Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .
|
-
-
- HY-15461S1
-
|
Ertugliflozin-d9 is deuterated labeled Ertugliflozin (HY-15461). Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2 . Has the potential for the treatment of type 2 diabetes mellitus .
|
-
-
- HY-B2099S
-
|
Buformin-d9 (hydrochloride) is the deuterium labeled Buformin. Buformin (1-Butylbiguanide), a potent AMPK activator, acts as an orally active biguanide antidiabetic agent. Buformin decreases hepatic gluconeogenesis and lowers blood glucose production in vivo. Buformin also has anti-cancer activities and is applied in cancer study (such as, cervical cancer and breast cancer, et al) .
|
-
-
- HY-14806S2
-
|
Teneligliptin-d5 (MP-513-d5) is deuterium labeled Teneligliptin. Teneligliptin (MP-513) hydrobromide hydrate is an orally active and selective dipeptidyl peptidase 4 (DPP-4) inhibitor (IC50s: 0.37 and 0.29 nM for the human and rat DPP-4, respectively). Teneligliptin hydrobromide hydrate improves blood glucose levels and can be used in researches related to type 2 diabetes mellitus .
|
-
-
- HY-W011012S
-
|
Adenosine 5'-monophosphate- 13C (disodium) is a 13C-labeled Adenosine 5'-monophosphate (HY-W011012). Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes .
|
-
-
- HY-W011012S1
-
|
Adenosine 5'-monophosphate-d2 disodium is the deuterium labeled Adenosine 5'-monophosphate (HY-W011012). Adenosine 5'-monophosphate disodium is an orally active purine nucleotide, and participates in ATP metabolism. Adenosine 5'-monophosphate disodium is also a ligand for adenosine 2B receptor. Adenosine 5'-monophosphate disodium can activate AMPK in skeletal muscle, and ameliorates insulin resistance and impaired glucose metabolism. Adenosine 5'-monophosphate disodium can be used for research of diabetes .
|
-
-
- HY-B0239S2
-
|
Threo-Chloramphenicol-d6 is the deuterium labeled Chloramphenicol . Chloramphenicol is an orally active, potent and broad-spectrum antibiotic. Chloramphenicol shows antibacterial activity. Chloramphenicol represses the oxygen-labile transcription factor and hypoxia inducible factor-1 alpha (HIF-1α) in hypoxic A549 and H1299 cells. Chloramphenicol suppresses the mRNA levels of vascular endothelial growth factor (VEGF) and glucose transporter 1, eventually decreasing VEGF release. Chloramphenicol can be used for anaerobic infections and lung cancer research .
|
-
-
- HY-W014901S1
-
|
Bisphenol F- 13C12 is the 13C labeled Bisphenol F (HY-W014901). Bisphenol F is an orally active endocrine disruptor. Bisphenol F promotes ROS generation, upregulates p-AKT/p-GSK3β, and induces Apoptosis. Bisphenol F interferes with glucose metabolism, affects neurodevelopment and reproductive function. Bisphenol F reduces social novelty preference in mouse offspring. Bisphenol F can be used in bone, blood, and fat-related studies. Bisphenol F is used as a substitute for Bisphenol A (HY-18260) .
|
-
-
- HY-W014901S
-
|
Bisphenol F- 13C6 is the 13C labeled Bisphenol F (HY-W014901). Bisphenol F is an orally active endocrine disruptor. Bisphenol F promotes ROS generation, upregulates p-AKT/p-GSK3β, and induces Apoptosis. Bisphenol F interferes with glucose metabolism, affects neurodevelopment and reproductive function. Bisphenol F reduces social novelty preference in mouse offspring. Bisphenol F can be used in bone, blood, and fat-related studies. Bisphenol F is used as a substitute for Bisphenol A (HY-18260) .
|
-
-
- HY-N2362S8
-
|
DL-Alanine-d7 (DL-2-Aminopropionic acid-d7) is deuterium labeled DL-Alanine. DL-alanine, an orally active amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .
|
-
-
- HY-N2362S9
-
|
DL-Alanine- 13C2, 15N (DL-2-Aminopropionic acid- 13C2, 15N) is 13C and 15N labeled DL-Alanine. DL-alanine, an orally active amino acid, is the racemic compound of L- and D-alanine. DL-alanine is employed both as a reducing and a capping agent, used with silver nitrate aqueous solutions for the production of nanoparticles. DL-alanine can be used for the research of transition metals chelation, such as Cu(II), Zn(II), Cd(11). DL-alanine, a sweetener, is classed together with glycine and sodium saccharin. DL-alanine plays a key role in the glucose-alanine cycle between tissues and liver .
|
-
Cat. No. |
Product Name |
|
Classification |
-
- HY-173115
-
|
|
Alkynes
|
15-LOX-IN-2 (Compound 2a) is an orally active COX-2/15-LOX inhibitor and a partial agonist of PPARγ. 15-LOX-IN-2 has anti-inflammatory activity and inhibits the levels of 20-HETE, IL-1β and TNF-α in RAW 264.7 cells treated with LPS (HY-D1056). In addition, 15-LOX-IN-2 has significant glucose uptake capacity in the absence of insulin. 15-LOX-IN-2 can be used for the research of metabolic diseases .
|
Cat. No. |
Product Name |
|
Classification |
-
- HY-W040040
-
|
|
Emulsifiers
Chelating Agents
Solubilizing Agents
|
γ-Cyclodextrin is an orally active cyclic oligosaccharide composed of eight glucose molecules, which can be formed by bacteria digesting starch. γ-Cyclodextrin can form water-soluble inclusion complexes with a variety of poorly soluble compounds and is widely used in fields such as pharmacy and food. In addition, γ-Cyclodextrin has good safety .
|
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent: